Post-finasteride syndrome | Anais Brasileiros de Dermatologia (Portuguese)

array:22 ["pii" => "S0365059620300970" "issn" => "03650596" "doi" => "10.1016/j.abd.2020.02.001" "estado" => "S300" "fechaPublicacion" => "2020-05-01" "aid" => "186" "copyrightAnyo" => "2020" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by/4.0/" "subdocumento" => "fla" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "pt" => array:18 [ "pii" => "S266627522030165X" "issn" => "26662752" "doi" => "10.1016/j.abdp.2020.02.001" "estado" => "S300" "fechaPublicacion" => "2020-05-01" "aid" => "186" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by/4.0/" "subdocumento" => "fla" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "pt" => array:11 [ "idiomaDefecto" => true "cabecera" => "Educação médica continuada" "titulo" => "Síndrome pós‐finasterida" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "tieneResumen" => "pt" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "271" "paginaFinal" => "277" ] ] "contieneResumen" => array:1 [ "pt" => true ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ana Francisca Junqueira Ribeiro Pereira, Thaissa Oliveira de Almeida Coelho" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Ana Francisca Junqueira Ribeiro" "apellidos" => "Pereira" ] 1 => array:2 [ "nombre" => "Thaissa Oliveira de Almeida" "apellidos" => "Coelho" ] ] ] ] ] "idiomaDefecto" => "pt" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0365059620300970" "doi" => "10.1016/j.abd.2020.02.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059620300970?idApp=UINPBA00008Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S266627522030165X?idApp=UINPBA00008Z" "url" => "/26662752/0000009500000003/v1_202006250813/S266627522030165X/v1_202006250813/pt/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S0365059620300933" "issn" => "03650596" "doi" => "10.1016/j.abd.2019.09.028" "estado" => "S300" "fechaPublicacion" => "2020-05-01" "aid" => "182" "copyright" => "Sociedade Brasileira de Dermatologia" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by/4.0/" "subdocumento" => "fla" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Investigation" "titulo" => "Immunostaining study of cytokeratins in human hair follicle development" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "278" "paginaFinal" => "282" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1034 "Ancho" => 1500 "Tamanyo" => 307946 ] ] "descripcion" => array:1 [ "en" => "Cytokeratin's immunostaining in human hair follicle development. (A) CK1 immunoexpression at 19 weeks fetus. (B) CK14 immunoexpression at 12 weeks fetus. (C) CK20 immunoexpression at 21 weeks fetus. (D) CK16 immunoexpression at 12 weeks fetus." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Laura Maria Andrade Silva, Ricardo Hsieh, Silvia Vanessa Lourenço, Neusa Yuriko Sakai Valente, Geise Rezende Paiva, Juliana Dumet Fernandes" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Laura Maria Andrade" "apellidos" => "Silva" ] 1 => array:2 [ "nombre" => "Ricardo" "apellidos" => "Hsieh" ] 2 => array:2 [ "nombre" => "Silvia Vanessa" "apellidos" => "Lourenço" ] 3 => array:2 [ "nombre" => "Neusa Yuriko Sakai" "apellidos" => "Valente" ] 4 => array:2 [ "nombre" => "Geise Rezende" "apellidos" => "Paiva" ] 5 => array:2 [ "nombre" => "Juliana Dumet" "apellidos" => "Fernandes" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "pt" => array:9 [ "pii" => "S2666275220301648" "doi" => "10.1016/j.abdp.2019.09.012" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275220301648?idApp=UINPBA00008Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059620300933?idApp=UINPBA00008Z" "url" => "/03650596/0000009500000003/v4_202007210853/S0365059620300933/v4_202007210853/en/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "Continuing Medical Education" "titulo" => "Post-finasteride syndrome" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "271" "paginaFinal" => "277" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Ana Francisca Junqueira Ribeiro Pereira, Thaissa Oliveira de Almeida Coelho" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Ana Francisca Junqueira Ribeiro" "apellidos" => "Pereira" "email" => array:1 [ 0 => "anafranciscadermato@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Thaissa Oliveira de Almeida" "apellidos" => "Coelho" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Trichology Outpatient Clinic, Dermatology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "textoCompleto" => "IntroductionFinasteride is an inhibitor of the enzyme 5α-reductase types 1 and 2 – with greater affinity for type 2 – that has been approved by the Food and Drug Administration (FDA) in the United States for the treatment of benign prostatic hyperplasia (BPH) since 1992 and for the treatment of male androgenetic alopecia (AGA) since 1997.<a class="elsevierStyleCrossRef" href="#bib0240">1</a>With a short half-life ranging from 4.7 to 7.1h,<a class="elsevierStyleCrossRef" href="#bib0240">1</a> it is able to significantly reduce serum, prostatic, and scalp levels of dihydrotestosterone (DHT), in addition to slightly raising testosterone levels,<a class="elsevierStyleCrossRef" href="#bib0245">2</a> generally without exceeding the reference values for the latter.Over time, several studies have demonstrated that finasteride is a safe and well-tolerated drug, with rare and reversible side effects such as reduced sexual libido and ejaculatory volume, most commonly observed when prescribed in a daily dose of 5mg for cases of BPH.<a class="elsevierStyleCrossRef" href="#bib0240">1</a>However, reports of adverse reactions related to finasteride that persisted for at least three months after its discontinuation have emerged in the past decade. The term post-finasteride syndrome (PFS) includes persistent sexual, neuropsychiatric, and physical adverse reactions in patients who used this drug.As a result, regulatory agencies in several countries generated warnings about this drug; in 2012, the FDA demanded changes in the package insert in the United States, including the possibility of persistent side effects.<a class="elsevierStyleCrossRef" href="#bib0250">3</a> In 2015, PFS was included in the list of Rare and Genetic Diseases of the National Institutes of Health (NIH).<a class="elsevierStyleCrossRef" href="#bib0255">4</a>Symptoms of PFS include decrease or complete loss of libido, low or no reaction to sexual stimulation, erectile dysfunction, loss of pleasure or absence of sensation in orgasm, loss of genital sensitivity, decrease in ejaculated volume, poor semen quality and infertility, penis shrinkage, abnormal penis curvature (Peyronie's disease), testicular pain, testicular reduction, gynecomastia, chronic fatigue, muscle weakness, muscle atrophy and/or pain, muscle spasms, joint pain, dry skin, memory problems, slow thinking, comprehension difficulties, depression (including suicidal thoughts), anxiety disorder, panic attacks, emotional detachment, and insomnia.<a class="elsevierStyleCrossRef" href="#bib0260">5</a>Finasteride and sexual adverse effectsAlbeit uncommon, sexual dysfunction secondary to finasteride use is a known adverse effect that involves loss of libido, in addition to erectile and ejaculatory disorders. More recently, sexual anhedonia, changes in the structure of the penis, and reduced penile sensitivity have also been reported. However, the persistence of these symptoms after the discontinuation of the drug is still a matter of controversy in the scientific community; to date, there are no studies that adequately assess this issue.After 15 years of FDA approval of the use of finasteride for AGA, in a retrospective study, Irwig et al. interviewed 71 men who reported persistent sexual side effects after three months of discontinuing the drug, which was used for AGA treatment at a daily dose of 1mg, with a mean use of 28 weeks and mean symptom duration of 40 weeks.<a class="elsevierStyleCrossRef" href="#bib0265">6</a> However, these patients were selected primarily in an online discussion forum aimed at individuals with sexual complaints after the use of 5α-reductase inhibitors, which constitutes an important selection bias. After 14 months, the same authors re-interviewed these patients, and 89% still reported adverse sexual effects.<a class="elsevierStyleCrossRef" href="#bib0270">7</a> Another retrospective study, conducted in 2016, of 79 individuals who received finasteride at a daily dose of 1mg for a mean of 27 months and developed long-lasting adverse effects, demonstrated persistence of symptoms for almost four years after treatment discontinuation.<a class="elsevierStyleCrossRef" href="#bib0275">8</a>These findings, however, are in contrast with previous studies that demonstrated the safety of finasteride. In 2003, a large double-blinded placebo-controlled clinical trial assessed the incidence of sexual side effects with the use of finasteride at a daily dose of 5mg.<a class="elsevierStyleCrossRef" href="#bib0280">9</a> Among patients who discontinued the drug due to sexual dysfunction, the persistence of symptoms was greater in the placebo group when compared with the treatment group, suggesting that the drug was probably not involved in the persistence of the complaints.<a class="elsevierStyleCrossRef" href="#bib0280">9</a>Two recent meta-analyses that assessed the incidence of sexual adverse effects did not directly address the persistence of symptoms.<a class="elsevierStyleCrossRefs" href="#bib0285">10,11</a> A systematic review and meta-analysis conducted in 2016 observed a significantly greater risk of sexual dysfunction among patients with BPH, but not in those undergoing AGA treatment.<a class="elsevierStyleCrossRef" href="#bib0285">10</a> The two divergent factors between the two groups that probably influenced these findings were the mean age and the daily dose used for each disease. Moreover, persistent symptoms were not evaluated. Conflicting results were found by another 2019 meta-analysis, which identified a two-fold increased risk of sexual dysfunction with the use of finasteride to treat AGA when compared with placebo.<a class="elsevierStyleCrossRef" href="#bib0290">11</a> However, the persistence of symptoms was also not analyzed in the included studies, and remains unclear.In this sense, a randomized double-blinded study with 117 men assessed persistent sexual side effects in patients allocated to dutasteride or placebo.<a class="elsevierStyleCrossRef" href="#bib0295">12</a> During its use, the incidence of sexual adverse reactions was twice as high in the dutasteride group, and symptom onset occurred primarily in the first three months of treatment. However, most symptoms were resolved during treatment; those that persisted were resolved within three to six weeks after treatment discontinuation.<a class="elsevierStyleCrossRef" href="#bib0295">12</a>In contrast, a 2017 retrospective cohort involving 4284 men aged 16 to 42 years who used finasteride at a daily dose of less than 1.25mg, with a median of 4 years after suspension, observed a rate of 0.8% of persistent sexual symptoms.<a class="elsevierStyleCrossRef" href="#bib0300">13</a> Of the 103 men who experienced sexual symptoms during treatment, 33% reported they persisted after suspension. The main independent predictor was use for a period longer than seven months.<a class="elsevierStyleCrossRef" href="#bib0300">13</a> This finding is in agreement with data from the previous retrospective study by Irwig et al., in which the onset of symptoms in patients with persistent complaints occurred after one year of using finasteride, although few had reported adverse effects in the first month of use.<a class="elsevierStyleCrossRef" href="#bib0265">6</a>Therefore, the current literature data are controversial, and it is not yet possible to establish a causal relationship between 5α-reductase inhibitors and the persistence of sexual symptoms. The studies that demonstrated a higher incidence of persistent side effects related to the use of finasteride have important biases and included limited samples, and are insufficient to confirm the existence of PFS. Likewise, they also do not allow distinguishing between a real adverse effect or a nocebo reaction to the medication. This nocebo effect was well documented in a study comparing patients who received counseling prior to finasteride treatment regarding the possibility of sexual side effects and those who had not; 43.6% of the patients who were informed presented symptoms, compared with 15.3% of the other group.<a class="elsevierStyleCrossRef" href="#bib0305">14</a> The nocebo effect may also be related to the occurrence of persistent sexual complaints.Men with persistent sexual symptoms after discontinuation of finasteride for AGA did not present a corresponding hormonal dysfunction, with maintenance of normal serum levels of testosterone and DHT, nor did they show loss of peripheral sensitivity to androgens or permanent inhibition of androgen receptors.<a class="elsevierStyleCrossRef" href="#bib0310">15</a>In order to elucidate the pathophysiology of PFS, animal studies were carried out and suggested changes in penile histology and architecture after the use of 5α-reductase inhibitors, with a decrease in smooth muscle and an increase in collagen in the penis after treatment with dutasteride.<a class="elsevierStyleCrossRef" href="#bib0315">16</a> A human study compared the histological foreskin findings in individuals with permanent sexual symptoms six months after finasteride withdrawal and found a difference in androgen receptor density when compared with those without prior exposure to 5α-reductase inhibitors,<a class="elsevierStyleCrossRef" href="#bib0320">17</a> but the data were not compared to those of previous users without persistent symptoms. Although these were small studies, they provide histological evidence of potentially permanent penile structural changes after the use of 5α-reductase inhibitors. However, it is not possible to establish a causal relationship between the findings or to draw definitive conclusions about their clinical significance.Finasteride and infertilityThe impact of 5α-reductase inhibitors on male fertility is another topic of debate. In two different analyses by Samplaski et al. with populations of men who sought treatment at infertility clinics, only 0.6% and 0.9% of them were finasteride users, from a total of 4400 and 4287 individuals, respectively.<a class="elsevierStyleCrossRefs" href="#bib0325">18,19</a>Researchers had previously demonstrated a negative impact of finasteride on the spermatogenesis of rats.<a class="elsevierStyleCrossRef" href="#bib0335">20</a> However, Overstreet et al. found that finasteride at a daily dose of 1mg did not alter spermatogenesis, semen production, or sperm morphology in healthy young men.<a class="elsevierStyleCrossRef" href="#bib0340">21</a> This was the largest randomized, controlled, double-blinded study on the impact of using 1mg finasteride on spermatogenesis, assessing 79 patients without any reproductive system alterations or history of infertility. The results showed no change in semen volume or sperm concentration and motility after 48 weeks of using the drug. Subjects were reassessed 60 weeks after discontinuation, and no relevant changes were observed, except for a recovery in prostate volume, which was reduced during treatment. Likewise, no changes in gonadotropin or testosterone levels were detected. Testosterone, not DHT, appears to be the main androgen regulating spermatogenesis.<a class="elsevierStyleCrossRef" href="#bib0340">21</a>Glina et al. reported three cases of young patients with semen quality disorders during treatment with finasteride.<a class="elsevierStyleCrossRef" href="#bib0345">22</a> All three patients presented abnormal concentration and altered sperm motility when using finasteride at a daily dose of 1mg. These changes were completely reversed (patients 1 and 2) or improved (patient 3) three or four months after treatment interruption. Two patients had varicocele on the left and the other was obese, leading the researchers to suggest that finasteride does not markedly alter the spermatogenesis process in healthy men, but in patients with infertility-related conditions, the negative effect of the drug could be amplified.<a class="elsevierStyleCrossRef" href="#bib0345">22</a>Corroborating this hypothesis, in the retrospective study by Samplaski et al., conducted in 2013, the impact of the same daily dose of 1mg of finasteride on the sperm count of 14 men with a history of infertility was analyzed, with a mean use of 57 months (2–120 months), and mean time from treatment interruption to repeat spermogram of 6.45 months (2–18 months).<a class="elsevierStyleCrossRef" href="#bib0325">18</a> That study demonstrated an 11.6-fold mean increase in sperm concentration after finasteride discontinuation. In the first analysis, seven of these patients presented critical sperm levels (below 5million/mL), reaching levels above 20million/mL after treatment interruption.<a class="elsevierStyleCrossRef" href="#bib0325">18</a> There was also an increase in sperm motility, but not statistically significant.<a class="elsevierStyleCrossRef" href="#bib0325">18</a> This was the only study that assessed the impact on individuals with conditions that predisposed to infertility.Liu et al. and Chiba et al. reported cases of infertile patients with azoospermia or oligospermia who showed significant improvement in sperm concentration after discontinuation of finasteride at a dose of 1mg; those authors also suggested that the drug may aggravate cases of subfertility or infertility.<a class="elsevierStyleCrossRefs" href="#bib0350">23,24</a>Other aspects that could affect spermatogenesis in finasteride users include a higher sperm DNA fragmentation rate, demonstrated in a case report,<a class="elsevierStyleCrossRef" href="#bib0360">25</a> and an eventual epididymis dysfunction, proposed in a study in rats<a class="elsevierStyleCrossRef" href="#bib0365">26</a>; however, none of these effects persisted after treatment was stopped.In 2007, a multicenter, randomized, double-blinded study with 99 healthy men with normal sperm parameters compared the use of finasteride at a dose of 5mg, dutasteride 0.5mg, and placebo, showing a mean reduction of 30% in sperm count and 6–12% in motility after six months in the finasteride and dutasteride groups.<a class="elsevierStyleCrossRef" href="#bib0370">27</a> However, after one year of using one of the drugs, an improvement was observed in the sperm count; the reduction only remained statistically significant in the dutasteride group.<a class="elsevierStyleCrossRef" href="#bib0370">27</a> Regarding the persistent findings in the dutasteride group, the reduction in sperm volume and count was maintained after six months of discontinuation of the drug.<a class="elsevierStyleCrossRef" href="#bib0370">27</a> Both drugs were associated with loss of sperm motility six months after treatment suspension. No alterations in sperm morphology were observed in any group. The repercussion of the findings on spermatogenesis was below the level pre-established as critical by the researchers, and the mean alterations observed would probably not have clinical significance in human reproduction.<a class="elsevierStyleCrossRef" href="#bib0370">27</a> Only three of these patients were more sensitive to the drug and reached counts as low as 10% of their baseline during treatment, one of whom used finasteride and the other two, dutasteride. These more severe cases presented partial recovery six months after drug suspension. The authors suggested the possibility of an individual variability in the response to 5α-reductase inhibitors.<a class="elsevierStyleCrossRef" href="#bib0370">27</a>Finasteride and neuropsychiatric adverse effectsNeuroactive steroids comprise steroid hormones synthesized in peripheral glands acting on the central nervous system (CNS), as well as neurosteroids produced in the brain itself.<a class="elsevierStyleCrossRef" href="#bib0375">28</a> The main neuroactive steroids are pregnenolone (PREG), dehydroepiandrosterone (DHEA), progesterone, testosterone, and 17β-estradiol, which have important physiological regulatory actions, such as neuroendocrine control in reproduction and sexual behavior, adjustment of synaptic plasticity, and cytoskeletal protein regulation, in addition to acting in the morphology of neurons and astrocytes, in the myelin compartment, in adult neurogenesis, and in functions related to cognition.<a class="elsevierStyleCrossRef" href="#bib0375">28</a>The three isoforms of 5α-reductase have already been identified in the brain, and the physiological role of type 3 of the enzyme is the most explored so far.<a class="elsevierStyleCrossRef" href="#bib0375">28</a> In the CNS, progesterone and testosterone are metabolized by the enzyme 5α-reductase into dehydroprogesterone (DHP) and DHT, respectively, which are soon converted into more metabolites, such as tetrahydroprogesterone (THP), isopregnanolone, 5α-androstane-3α, 17β-diol, and 5α-androstane-3β,17β-diol, whose action occurs through classic (androgen, estrogen, and progestogen receptors) and non-classic receptors (GABA-A receptors).In the assessment of neuropsychiatric adverse effects related to 5α-reductase inhibitors, randomized controlled studies are lacking. Pre-clinical studies have demonstrated a reduction in neurosteroid levels. Of the clinical studies, very few are prospective; the remaining literature is restricted to case reports, reporting depression and anxiety without association with sexual dysfunction in finasteride users, with improvement in symptoms after drug discontinuation and early recurrence of symptoms with treatment reinitiation.<a class="elsevierStyleCrossRef" href="#bib0380">29</a> Persistent symptoms were reported in only three retrospective studies. One of them, conducted in 2011 without a control group, reported complaints of depression, suicidal ideation, and persistent sexual symptoms in former finasteride users.<a class="elsevierStyleCrossRef" href="#bib0265">6</a> In 2015, Ganzer et al. assessed 131 individuals with persistent complaints, most of whom, unusually, started to present symptoms after the medication was discontinued.<a class="elsevierStyleCrossRef" href="#bib0260">5</a> At the same time, a pharmacovigilance study identified 4910 reports of persistent symptoms related to finasteride over 15 years.<a class="elsevierStyleCrossRef" href="#bib0385">30</a> Among them, there were 39 cases (0.79%) of suicidal ideation, and 34 of these patients also had persistent erectile dysfunction.<a class="elsevierStyleCrossRef" href="#bib0385">30</a> Thus, it was not possible to determine whether suicidal ideation is associated with finasteride and/or with the concomitant sexual disorders.<a class="elsevierStyleCrossRef" href="#bib0385">30</a>Persistent changes in neuroactive steroids have been documented in rodent brains after finasteride discontinuation.<a class="elsevierStyleCrossRef" href="#bib0390">31</a>A prospective multicenter longitudinal clinical study conducted in 2017 observed abnormalities in plasma levels and cerebrospinal fluid (CSF) of neuroactive steroids in individuals with persistent symptoms after finasteride suspension.<a class="elsevierStyleCrossRef" href="#bib0375">28</a> The case group was formed by healthy men aged between 22 and 44 years who used 1–1.25mg of finasteride daily, suspended for at least three months, and who did not use other drugs with potential side effects, nor had a history of depression or sexual dysfunction. A total of 16 individuals with PFS were recruited, with 14 remaining at the end of the study, of whom 11 had their hormones levels measured in blood and CSF (PREG, progesterone, DHEA, DHP, DHT, testosterone, THP, isopregnenolone, 17β-estradiol, 3α- and 3β-diol), in addition to 25 controls. The levels of PREG, as well as progesterone and DHP, were significantly reduced in the CSF of patients with PFS, and those of DHEA and testosterone significantly elevated, with a reduction in DHT and 17β-estradiol. In plasma, an increase in DHEA and testosterone was also observed, but PREG was very high.<a class="elsevierStyleCrossRef" href="#bib0375">28</a> That study presents as a bias the fact that patients were recruited through a website aimed at men with complaints related to finasteride. It was concluded that finasteride not only affects the levels of 5α-reduced metabolites of progesterone and testosterone, as would be expected, but also changes other metabolites and precursors, suggesting that this has a wider consequence in the levels of neuroactive steroids in patients with PFS.<a class="elsevierStyleCrossRef" href="#bib0375">28</a> Of the 16 PFS patients in this study, eight had major depression. The hypothesis that testosterone levels may not be predictive of erectile dysfunction or depression, but rather DHT levels, was raised; a possible association between reduced progesterone levels and depressive symptoms was suggested. The possibility that erectile dysfunction is related to peripheral neuropathy was also raised, since those authors also observed a reduction in the evoked potential of the pudendal nerve.<a class="elsevierStyleCrossRef" href="#bib0375">28</a>A 2019 study detected, even after drug discontinuation, a reduction in progesterone levels and their corresponding metabolites – DHP and THP – and an increase in its precursor PREG, in addition to a drastic drop in the level of DHT and an increase in CSF testosterone.<a class="elsevierStyleCrossRef" href="#bib0395">32</a> In plasma, a reduction in DHP and 17β-estradiol was observed. In conclusion, the authors indicated that previous sexual and/or psychological conditions would lead to a greater risk and magnitude of adverse reactions to finasteride, and it is important to assess sexual dysfunction and psychiatric disorders before starting the medication.<a class="elsevierStyleCrossRef" href="#bib0395">32</a>Following this same idea, in 2018, a study included 97 men aged 18 years or older who reported persistent adverse effects after using finasteride at a daily dose of 1mg for at least three months, excluding those with basic sexual dysfunction and non-confirmed psychiatric diagnosis.<a class="elsevierStyleCrossRef" href="#bib0400">33</a> Of the participants, 55% had had a psychiatric diagnosis prior to the use of finasteride and 28.8% had a history of psychiatric diagnosis in a first-degree relative; 11.3% had both. After discontinuing the drug, 34% reported anxiety and 49.3% depression; in 79.2% of those with depression, the condition was classified as moderate to severe, and in 10.4%, as severe.<a class="elsevierStyleCrossRef" href="#bib0400">33</a> The researchers also reinforced the need for screening for a previous psychiatric history and counseling on the potential psychological consequences of using finasteride in predisposed individuals, weighing the risks and benefits of treatment.<a class="elsevierStyleCrossRef" href="#bib0400">33</a>A retrospective study conducted in 2016 with 79 men aged 18 to 50 years old demonstrated anhedonia as the most frequent non-sexual symptom, occurring in 75.9% of patients; 72.2% complained of difficulty in focusing.<a class="elsevierStyleCrossRef" href="#bib0275">8</a> In addition to the small sample, it is important to note the selection bias of that study, since subjects were invited to participate after having answered a survey on a PFS-awareness website.In turn, it is important to remember that the studies carried out so far do not allow establishing a causal relationship between symptoms and the use of finasteride, and the prevalence of these events has not been calculated.<a class="elsevierStyleCrossRef" href="#bib0405">34</a>Finasteride and metabolic and cardiovascular eventsBy altering steroid metabolism, 5α-reductase inhibitors may contribute to insulin resistance,<a class="elsevierStyleCrossRefs" href="#bib0410">35–39</a> increasing the predisposition to diabetes, hepatic steatosis,<a class="elsevierStyleCrossRefs" href="#bib0425">38,40</a> alteration of body fat distribution,<a class="elsevierStyleCrossRefs" href="#bib0420">37,38</a> metabolic syndrome, and cardiovascular diseases, since they reduce the clearance of glucocorticoids and mineralocorticoids.<a class="elsevierStyleCrossRef" href="#bib0415">36</a>In a study of metabolic dysfunction in patients treated with finasteride or dutasteride compared with controls, inhibition of both isoforms (1 and 2) of the enzyme 5α-reductase by dutasteride was associated with higher peripheral insulin levels.<a class="elsevierStyleCrossRef" href="#bib0440">41</a>A preclinical study corroborated these findings. The absence of type 1 isoenzyme 5α-reductase was associated, in rats, with hepatic steatosis, insulin resistance, and changes in the distribution of body fat.<a class="elsevierStyleCrossRef" href="#bib0425">38</a>The metabolic implications would be more significant with dutasteride, but more clinical studies are needed to confirm such effects in users of 5α-reductase inhibitors. It is also important to discuss screening for metabolic syndrome and insulin resistance in 5α-reductase inhibitors candidates over 35 years of age with risk factors, which may account for over half of the candidates.<a class="elsevierStyleCrossRef" href="#bib0410">35</a>With regard to the risk of cardiovascular damage, to date such have not been assessed with outcomes in clinical studies,<a class="elsevierStyleCrossRef" href="#bib0420">37</a> hindering the determination of a causal relationship between the findings. To date, the information on this subject is limited, since the relevant variables have not been analyzed in most studies.<a class="elsevierStyleCrossRef" href="#bib0430">39</a>Even bone metabolism may be altered,<a class="elsevierStyleCrossRefs" href="#bib0420">37,42</a> and a case–control study recently demonstrated an increased risk of osteoporosis in finasteride users at a daily dose of 5mg, with evidence that it is a dose-dependent risk.<a class="elsevierStyleCrossRef" href="#bib0445">42</a> The association between use of a 5α-reductase inhibitor and loss of bone density and muscle strength was also suggested in an animal model, in a study conducted in 2011 by Windahl et al.<a class="elsevierStyleCrossRef" href="#bib0450">43</a>; however, these are preliminary data, and there is still no strong enough evidence to support a prior bone density assessment in finasteride candidates.Final considerationsDespite all the doubts and fears raised by the reports in the last years, finasteride is still considered a safe drug. The aforementioned pharmacovigilance study conducted in 2015 collected few reports of persistent side effects related to the drug over 15 years; nonetheless, it is not possible to establish a causal relationship with the drug in many cases, since other disorders were present.<a class="elsevierStyleCrossRef" href="#bib0385">30</a>In 2016, Arias-Santiago et al. raised the hypothesis of nocebo effect, discussing whether the cause of the adverse effects of finasteride was more psychological than pharmacological.<a class="elsevierStyleCrossRef" href="#bib0430">39</a> The authors also highlighted the emotional impact and self-esteem problems that AGA itself would cause, and that this would serve as a confounding factor in the assessment of the occurrence of psychiatric and sexual symptoms in finasteride users. However, those authors observed that lower levels of certain steroid hormones could explain the symptoms reported in the literature, even suggesting the use of a lower daily dose of finasteride in patients concerned about side effects.<a class="elsevierStyleCrossRef" href="#bib0430">39</a>In the future, the measurement of dopamine and serotonin levels in individuals with PFS may elucidate many issues, since the pathways of these neurotransmitters can be altered in neurosteroidogenesis disorders, which in itself would affect sexual behavior in these patients.<a class="elsevierStyleCrossRef" href="#bib0455">44</a>The possibility that epigenetic mechanisms may influence the occurrence of PFS is also discussed, as it appears to affect a limited number of individuals exposed to the drug.<a class="elsevierStyleCrossRef" href="#bib0455">44</a> Giatti et al. even raised the hypothesis that PFS has mechanisms in common with post-selective serotonin reuptake inhibitor syndrome, given the wide range of similar symptoms in the two clinical entities.<a class="elsevierStyleCrossRef" href="#bib0455">44</a>Finally, it is difficult to discriminate which physiological, endocrine, or neurological aspects are primary or secondary, and it is necessary to review the causality algorithms and to further analyze specific groups of patients, assessing each history in more detail, excluding the use of other drugs or relevant comorbidities, for example.<a class="elsevierStyleCrossRef" href="#bib0460">45</a>It is noteworthy that the prevalence and incidence of persistent adverse reactions to finasteride has never been established and that PFS is not yet fully recognized by the scientific community.<a class="elsevierStyleCrossRefs" href="#bib0465">46,47</a> Despite its homogeneous and characteristic symptoms, the literature to date has low scientific quality, which does not allow refuting or confirming PFS as a nosological entity; however, it should not be ignored. If it does exist, it appears to occur in susceptible individuals exposed even to small doses and for a short period, whose symptoms may persist for a long time.<a class="elsevierStyleCrossRef" href="#bib0405">34</a>Therefore, it is important to create practical recommendations in relation to patients’ eligibility for treatment with finasteride, as well as advising these individuals on possible risks, alternative drugs for the treatment of AGA, and how they should proceed in case of side effects.<a class="elsevierStyleCrossRefs" href="#bib0420">37,43</a>From the currently available data, the use of 5α-reductase inhibitors in individuals with a previous history of depression, sexual dysfunction, or infertility should be carefully assessed, and the decision should be individualized. Topical finasteride has been widely studied and may become a future alternative in the treatment of AGA.Financial supportNone declared.Authors' contributionsAna Francisca Junqueira Ribeiro Pereira: Approval of the final version of the manuscript; elaboration and writing of the manuscript; critical review of the literature; critical review of the manuscript.Thaissa Oliveira de Almeida Coelho: Approval of the final version of the manuscript; elaboration and writing of the manuscript; critical review of the literature; critical review of the manuscript.Conflicts of interestNone declared.<elsevierMultimedia ident="tbl0140"></elsevierMultimedia><elsevierMultimedia ident="tbl0005"></elsevierMultimedia>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres1365088" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1254920" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 3 => array:2 [ "identificador" => "sec0010" "titulo" => "Finasteride and sexual adverse effects" ] 4 => array:2 [ "identificador" => "sec0015" "titulo" => "Finasteride and infertility" ] 5 => array:2 [ "identificador" => "sec0020" "titulo" => "Finasteride and neuropsychiatric adverse effects" ] 6 => array:2 [ "identificador" => "sec0025" "titulo" => "Finasteride and metabolic and cardiovascular events" ] 7 => array:2 [ "identificador" => "sec0030" "titulo" => "Final considerations" ] 8 => array:2 [ "identificador" => "sec0035" "titulo" => "Financial support" ] 9 => array:2 [ "identificador" => "sec0040" "titulo" => "Authors' contributions" ] 10 => array:2 [ "identificador" => "sec0045" "titulo" => "Conflicts of interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2020-02-11" "fechaAceptado" => "2020-02-14" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1254920" "palabras" => array:3 [ 0 => "5-Alpha reductase inhibitors" 1 => "Alopecia" 2 => "Finasteride" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "Finasteride is a 5α-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997. Over time, it has been considered a safe and well-tolerated drug with rare and reversible side effects. Recently there have been reports of adverse drug-related reactions that persisted for at least three months after discontinuation of this drug, and the term post-finasteride syndrome arose. It includes persistent sexual, neuropsychiatric, and physical symptoms. Studies to date cannot refute or confirm this syndrome as a nosological entity. If it actually exists, it seems to occur in susceptible people, even if exposed to small doses and for short periods, and symptoms may persist for long periods. Based on currently available data, the use of 5α-reductase inhibitors in patients with a history of depression, sexual dysfunction, or infertility should be carefully and individually assessed." ] ] "NotaPie" => array:2 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "How to cite this article: Pereira AFJR, Coelho TOA. Post-finasteride syndrome. An Bras Dermatol. 2020;95:271–7." ] 1 => array:2 [ "etiqueta" => "☆☆" "nota" => "Study conducted at the Trichology Outpatient Clinic, Dermatology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil." ] ] "multimedia" => array:2 [ 0 => array:5 [ "identificador" => "tbl0140" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => false "mostrarDisplay" => true "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Questions EMC \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">1) Regarding finasteride, it is correct to state that: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">a) It has a long half-life, which could justify the reports of persistent adverse effects. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">b) It is able to dramatically increase serum DHT and testosterone. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">c) The occurrence of side effects related to the drug is not dose-dependent. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">d) A few years ago, a series of symptoms that appeared and even worsened after finasteride discontinuation have been attributed to the drug. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="1" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">2) Check the incorrect alternative on adverse sexual effects in post-finasteride syndrome: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">a) One of the main complaints is penile sensitivity reduction. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">b) Symptoms of this syndrome are considered to be those that persist after three weeks of drug discontinuation. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">c) Selection bias is the main limitation of studies that describe a higher incidence of these symptoms. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">d) The duration of finasteride use appears to be a risk factor for the onset of the syndrome. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="1" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">3) Regarding laboratory findings in individuals with post-finasteride syndrome, it is possible to state that: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">a) Serum testosterone levels are low and DHT levels are normal. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">b) Serum DHT levels are low and testosterone levels are normal. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">c) Serum testosterone and DHT levels are normal. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">d) Serum testosterone and DHT levels are low. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="1" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">4) In the pathophysiology of the persistent sexual effects of post-finasteride syndrome, it can be stated that: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">a) There is evidence of peripheral insensitivity to androgens. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">b) Human studies suggest changes in penile histology and architecture. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">c) There are signs of permanent inhibition of androgen receptors. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">d) The nocebo effect cannot be ruled out in such cases. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="1" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">5) Regarding finasteride and infertility, it is correct to state that: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">a) The drug is able to temporarily alter the sperm morphology. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">b) The decrease in fertility does not appear to be related to the dose used. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">c) There is a permanent reduction in the ejaculated volume. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">d) There is still insufficient data to state that finasteride interferes with the spermatogenesis of healthy men, without predisposing factors for infertility. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="1" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">6) The following alterations in the spermogram secondary to the use of finasteride are possible, except: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">a) Oligospermia \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">b) Sperm DNA fragmentation \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">c) Aberrations in sperm morphology \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">d) Reduction of sperm motility \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="1" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">7) Regarding neurosteroid hormones, it cannot be said that: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">a) By definition, these are hormones exclusively produced in the brain. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">b) Examples of neurosteroid hormones are pregnenolone, progesterone, and testosterone. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">c) In the central nervous system, progesterone and testosterone are metabolized by the enzyme 5α-reductase into, respectively, dihydroprogesterone and dihydrotestosterone. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">d) The levels of brain metabolites of the 5α-reductase enzyme are altered in degenerative and psychiatric diseases.. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="1" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">8) Regarding post-finasteride syndrome it is correct to state that: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">a) The possibility of a nocebo effect of the drug has already been ruled out. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">b) The risk of depression and anxiety disorder in finasteride users is independent of the presence of a concomitant sexual disorder. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">c) In the case of a personal history of underlying psychiatric illness, the use of finasteride is not indicated. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">d) Epigenetic mechanisms may explain the occurrence of the syndrome in only a limited number of individuals exposed to finasteride. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="1" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">9) Regarding the metabolic effects of finasteride, it is incorrect to state that: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">a) The drug appears to contribute to peripheral insulin resistance and diabetes. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">b) It changes the distribution of body fat and induces hepatic steatosis. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">c) Due to its influence on bone metabolism, a periodic bone density assessment in individuals using finasteride is mandatory. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">d) Faced with a possible increase in cardiovascular risk, more elaborate clinical studies that analyze countless relevant variables are necessary. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="1" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">10) When assessing a patient with an indication for the use of finasteride, the physician should consider: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">a) Presence of previous psychiatric or sexual disorders \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">b) Family history of psychiatric illnesses \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">c) Family history of infertility or subfertility \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">d) Risk factors for metabolic syndrome \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="1" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"></td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2344590.png" ] ] ] ] ] 1 => array:5 [ "identificador" => "tbl0005" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => false "mostrarDisplay" => true "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">AnswersUse of psychiatric drugs in dermatology. An Bras Dermatol. 2020;95(2):133-143.</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1. c \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3. c \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5. a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7. d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9. a \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2. c \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4. d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6. c \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8. d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10. b \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2344589.png" ] ] ] ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:47 [ 0 => array:3 [ "identificador" => "bib0240" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finasteride – an update and review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.C. Cather" 1 => "D. Lane" 2 => "M.R. Heaphy Jr." 3 => "B.R. Nelson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cutis" "fecha" => "1999" "volumen" => "64" "paginaInicial" => "167" "paginaFinal" => "172" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10500917" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0245" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "5α-Reductase: history and clinical importance" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "L.S. Marks" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Rev Urol" "fecha" => "2004" "volumen" => "6" "numero" => "Suppl. 9" "paginaInicial" => "S11" "paginaFinal" => "S21" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16985920" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0250" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Accessdata.fda.gov [Internet]. Propecia (finasteride). Available from: <a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process</a> [cited 26.10.19]." ] ] ] 3 => array:3 [ "identificador" => "bib0255" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Rarediseases.info.nih.gov [Internet]. Adverse events of 5-alpha-reductase inhibitors. Available from: <a target="_blank" href="https://rarediseases.info.nih.gov/diseases/12407/post-finasteride-syndrome">https://rarediseases.info.nih.gov/diseases/12407/post-finasteride-syndrome</a> [cited 26.10.19]." ] ] ] 4 => array:3 [ "identificador" => "bib0260" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C.A. Ganzer" 1 => "A.R. Jacobs" 2 => "F. Iqbal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1557988314538445" "Revista" => array:6 [ "tituloSerie" => "Am J Mens Health" "fecha" => "2015" "volumen" => "9" "paginaInicial" => "222" "paginaFinal" => "228" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24928450" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0265" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent sexual side effects of finasteride for male pattern hair loss" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M.S. Irwig" 1 => "S. Kolukula" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1743-6109.2011.02255.x" "Revista" => array:6 [ "tituloSerie" => "J Sex Med" "fecha" => "2011" "volumen" => "8" "paginaInicial" => "1747" "paginaFinal" => "1753" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21418145" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0270" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent sexual side effects of finasteride: could they be permanent?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M.S. Irwig" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1743-6109.2012.02846.x" "Revista" => array:6 [ "tituloSerie" => "J Sex Med" "fecha" => "2012" "volumen" => "9" "paginaInicial" => "2927" "paginaFinal" => "2932" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22789024" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0275" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "G. Chiriacò" 1 => "S. Cauci" 2 => "G. Mazzon" 3 => "C. Trombetta" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Andrology" "fecha" => "2016" "volumen" => "4" "paginaInicial" => "245" "paginaFinal" => "250" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0280" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Wessells" 1 => "J. Roy" 2 => "J. Bannow" 3 => "J. Grayhack" 4 => "A.M. Matsumoto" 5 => "L. Tenover" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0090-4295(02)02401-9" "Revista" => array:6 [ "tituloSerie" => "Urology" "fecha" => "2003" "volumen" => "61" "paginaInicial" => "579" "paginaFinal" => "584" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12639651" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0285" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of 5alpha-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Liu" 1 => "S. Zhao" 2 => "F. Li" 3 => "E. Li" 4 => "R. Kang" 5 => "L. Luo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jsxm.2016.07.006" "Revista" => array:6 [ "tituloSerie" => "J Sex Med" "fecha" => "2016" "volumen" => "13" "paginaInicial" => "1297" "paginaFinal" => "1310" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27475241" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0290" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Lee" 1 => "Y.B. Lee" 2 => "S.J. Choe" 3 => "W.S. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2340/00015555-3035" "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "2019" "volumen" => "99" "paginaInicial" => "12" "paginaFinal" => "17" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30206635" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0295" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.F. Tsai" 1 => "G.S. Choi" 2 => "B.J. Kim" 3 => "M.B. Kim" 4 => "C.F. Ng" 5 => "P. Kochhar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/1346-8138.14329" "Revista" => array:6 [ "tituloSerie" => "J Dermatol" "fecha" => "2018" "volumen" => "45" "paginaInicial" => "799" "paginaFinal" => "804" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29667763" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0300" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent erectile dysfunction in men exposed to the 5alpha-reductase inhibitors, finasteride, or dutasteride" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Kiguradze" 1 => "W.H. Temps" 2 => "P.R. Yarnold" 3 => "J. Cashy" 4 => "R.E. Brannigan" 5 => "B. Nardone" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7717/peerj.3020" "Revista" => array:5 [ "tituloSerie" => "PeerJ" "fecha" => "2017" "volumen" => "5" "paginaInicial" => "e3020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28289563" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0305" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finasteride 5mg and sexual side effects: how many of these are related to a nocebo phenomenon?" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Mondaini" 1 => "P. Gontero" 2 => "G. Giubilei" 3 => "G. Lombardi" 4 => "T. Cai" 5 => "A. Gavazzi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1743-6109.2007.00563.x" "Revista" => array:6 [ "tituloSerie" => "J Sex Med" "fecha" => "2007" "volumen" => "4" "paginaInicial" => "1708" "paginaFinal" => "1712" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17655657" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0310" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Basaria" 1 => "R. Jasuja" 2 => "G. Huang" 3 => "W. Wharton" 4 => "H. Pan" 5 => "K. Pencina" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/jc.2016-2726" "Revista" => array:6 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2016" "volumen" => "101" "paginaInicial" => "4669" "paginaFinal" => "4680" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27662439" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0315" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent erectile dysfunction after discontinuation of 5-alpha reductase inhibitor therapy in rats depending on the duration of treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.H. Sung" 1 => "J. Yu" 2 => "S.J. Kang" 3 => "M.R. Chae" 4 => "I. So" 5 => "J.K. Park" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5534/wjmh.180082" "Revista" => array:6 [ "tituloSerie" => "World J Mens Health" "fecha" => "2019" "volumen" => "37" "paginaInicial" => "240" "paginaFinal" => "248" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30588787" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0320" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C. Di Loreto" 1 => "F. La Marra" 2 => "G. Mazzon" 3 => "E. Belgrano" 4 => "C. Trombetta" 5 => "S. Cauci" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0100237" "Revista" => array:5 [ "tituloSerie" => "PLOS ONE" "fecha" => "2014" "volumen" => "9" "paginaInicial" => "e100237" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24959691" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0325" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finasteride use in the male infertility population: effects on semen and hormone parameters" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M.K. Samplaski" 1 => "K. Lo" 2 => "E. Grober" 3 => "K. Jarvi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.fertnstert.2013.07.2000" "Revista" => array:6 [ "tituloSerie" => "Fertil Steril" "fecha" => "2013" "volumen" => "100" "paginaInicial" => "1542" "paginaFinal" => "1546" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24012200" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0330" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reproductive endocrinologists are the gatekeepers for male infertility care in North America: results of a North American survey on the referral patterns and characteristics of men presenting to male infertility specialists for infertility investigations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.K. Samplaski" 1 => "J.F. Smith" 2 => "K.C. Lo" 3 => "J.M. Hotaling" 4 => "S. Lau" 5 => "E.D. Grober" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.fertnstert.2019.06.011" "Revista" => array:6 [ "tituloSerie" => "Fertil Steril" "fecha" => "2019" "volumen" => "112" "paginaInicial" => "657" "paginaFinal" => "662" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31351700" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0335" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Testosterone-dependent restoration of spermatogenesis in adult rats is impaired by a 5alpha-reductase inhibitor" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "L. O’Donnell" 1 => "K. Pratis" 2 => "P.G. Stanton" 3 => "D.M. Robertson" 4 => "R.I. McLachlan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Androl" "fecha" => "1999" "volumen" => "20" "paginaInicial" => "109" "paginaFinal" => "117" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10100481" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0340" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.W. Overstreet" 1 => "V.L. Fuh" 2 => "J. Gould" 3 => "S.S. Howards" 4 => "M.M. Lieber" 5 => "W. Hellstrom" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Urol" "fecha" => "1999" "volumen" => "162" "paginaInicial" => "1295" "paginaFinal" => "1300" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10492183" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0345" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finasteride-associated male infertility" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Glina" 1 => "P.A. Neves" 2 => "R. Saade" 3 => "N.R. Netto Jr." 4 => "J.B. Soares" 5 => "A.G. Galuppo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1590/s0041-87812004000400009" "Revista" => array:6 [ "tituloSerie" => "Rev Hosp Clin Fac Med Sao Paulo" "fecha" => "2004" "volumen" => "59" "paginaInicial" => "203" "paginaFinal" => "205" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15361986" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0350" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Propecia-induced spermatogenic failure: a report of two cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K.E. Liu" 1 => "S. Binsaleh" 2 => "K.C. Lo" 3 => "K. Jarvi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.fertnstert.2007.08.003" "Revista" => array:5 [ "tituloSerie" => "Fertil Steril" "fecha" => "2008" "volumen" => "90" "paginaInicial" => "849" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18625502" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0355" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finasteride-associated male infertility" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "K. Chiba" 1 => "K. Yamaguchi" 2 => "F. Li" 3 => "M. Ando" 4 => "M. Fujisawa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.fertnstert.2010.12.001" "Revista" => array:5 [ "tituloSerie" => "Fertil Steril" "fecha" => "2011" "volumen" => "95" "paginaInicial" => "1786" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21193189" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0360" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finasteride-induced secondary infertility associated with sperm DNA damage" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "H.Y. Tu" 1 => "A. Zini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.fertnstert.2011.01.025" "Revista" => array:4 [ "tituloSerie" => "Fertil Steril" "fecha" => "2011" "volumen" => "95" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21292256" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0365" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Actions of 5alpha-reductase inhibitors on the epididymis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B. Robaire" 1 => "N.A. Henderson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Mol Cell Endocrinol" "fecha" => "2006" "volumen" => "250" "paginaInicial" => "190" "paginaFinal" => "195" ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0370" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.K. Amory" 1 => "C. Wang" 2 => "R.S. Swerdloff" 3 => "B.D. Anawalt" 4 => "A.M. Matsumoto" 5 => "W.J. Bremner" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2007" "volumen" => "92" "paginaInicial" => "1659" "paginaFinal" => "1665" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0375" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.C. Melcangi" 1 => "D. Santi" 2 => "R. Spezzano" 3 => "M. Grimoldi" 4 => "T. Tabacchi" 5 => "M.L. Fusco" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jsbmb.2017.04.003" "Revista" => array:6 [ "tituloSerie" => "J Steroid Biochem Mol Biol" "fecha" => "2017" "volumen" => "171" "paginaInicial" => "229" "paginaFinal" => "235" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28408350" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0380" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finasteride induced depression: a prospective study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "B. Rahimi-Ardabili" 1 => "R. POurandarjani" 2 => "P. Habibollahi" 3 => "A. Mualeki" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1472-6904-6-7" "Revista" => array:5 [ "tituloSerie" => "BMC Clin Pharmacol" "fecha" => "2006" "volumen" => "6" "paginaInicial" => "7" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17026771" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0385" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.K. Ali" 1 => "B.S. Heran" 2 => "M. Etminan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/phar.1612" "Revista" => array:6 [ "tituloSerie" => "Pharmacotherapy" "fecha" => "2015" "volumen" => "35" "paginaInicial" => "687" "paginaFinal" => "695" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26133534" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0390" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of subchronic finasteride treatment and withdrawal on neuroactive steroid levels and their receptors in the male rat brain" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Giatti" 1 => "B. Foglio" 2 => "S. Romano" 3 => "M. Pesaresi" 4 => "G. Panzica" 5 => "L.M. Garcia-Segura" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000442982" "Revista" => array:6 [ "tituloSerie" => "Neuroendocrinology" "fecha" => "2016" "volumen" => "103" "paginaInicial" => "746" "paginaFinal" => "757" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26646518" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0395" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finasteride and androgenic alopecia; from therapeutic options to medical implications" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I.G. Motofei" 1 => "D.L. Rowland" 2 => "M. Tampa" 3 => "M.I. Sarbu" 4 => "M.I. Mitran" 5 => "C.I. Mitran" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Dermatolog Treat" "fecha" => "2019" "volumen" => "21" "paginaInicial" => "1" "paginaFinal" => "7" ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0400" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Emotional consequences of finasteride: fool's gold" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C.A. Ganzer" 1 => "A.R. Jacobs" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1557988316631624" "Revista" => array:6 [ "tituloSerie" => "Am J Mens Health" "fecha" => "2018" "volumen" => "12" "paginaInicial" => "90" "paginaFinal" => "95" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26868914" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0405" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Post-finasteride syndrome – does it really exist?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R.B. Maksym" 1 => "A. Kajdy" 2 => "M. Rabijewski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/13685538.2018.1548589" "Revista" => array:6 [ "tituloSerie" => "Aging Male" "fecha" => "2019" "volumen" => "22" "paginaInicial" => "250" "paginaFinal" => "259" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30651009" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0410" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Changes of metabolic profile in men treated for androgenetic alopecia with 1mg finasteride" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M. Duskova" 1 => "M. Hill" 2 => "L. Starka" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4149/endo_2010_01_3" "Revista" => array:6 [ "tituloSerie" => "Endocr Regul" "fecha" => "2010" "volumen" => "44" "paginaInicial" => "3" "paginaFinal" => "8" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20151762" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0415" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.M. Traish" 1 => "A.T. Guay" 2 => "M. Zitzmann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1515/hmbci-2014-0025" "Revista" => array:6 [ "tituloSerie" => "Horm Mol Biol Clin Investig" "fecha" => "2014" "volumen" => "20" "paginaInicial" => "73" "paginaFinal" => "80" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25460297" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0420" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adverse effects of 5α-reductase inhibitors: what do we know, don’t know, and need to know?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A.M. Traish" 1 => "R.C. Melcangi" 2 => "M. Bortolato" 3 => "L.M. Garcia-Segura" 4 => "M. Zitzmann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11154-015-9319-y" "Revista" => array:6 [ "tituloSerie" => "Rev Endocr Metab Disord" "fecha" => "2015" "volumen" => "16" "paginaInicial" => "177" "paginaFinal" => "198" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26296373" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0425" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.E. Livingstone" 1 => "P. Barat" 2 => "E.M. Di Rollo" 3 => "G.A. Rees" 4 => "B.A. Weldin" 5 => "E.A. Rog-Zielinska" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/db14-0249" "Revista" => array:6 [ "tituloSerie" => "Diabetes" "fecha" => "2015" "volumen" => "64" "paginaInicial" => "447" "paginaFinal" => "458" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25239636" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0430" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adverse effects of 5-alpha reductase inhibitor therapy in men with androgenetic alopecia: is there cause for concern?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Arias-Santiago" 1 => "F.M. Camacho-Martínez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2016.06.006" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2016" "volumen" => "107" "paginaInicial" => "709" "paginaFinal" => "711" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27436801" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0435" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Hazlehurst" 1 => "A.I. Oprescu" 2 => "N. Nikolaou" 3 => "R. Di Guida" 4 => "A.E. Grinbergs" 5 => "N.P. Davies" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2016" "volumen" => "101" "paginaInicial" => "103" "paginaFinal" => "113" ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0440" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "5α-Reductase type 1 modulates insulin sensitivity in men" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Upreti" 1 => "K.A. Hughes" 2 => "D.E. Livingstone" 3 => "C.D. Gray" 4 => "F.C. Minns" 5 => "D.P. Macfarlane" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2014" "volumen" => "99" "paginaInicial" => "1397" "paginaFinal" => "1406" ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0445" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A population-based nested case–control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "W.L. Lin" 1 => "Y.W. Hsieh" 2 => "C.L. Lin" 3 => "F.C. Sung" 4 => "C.H. Wu" 5 => "C.H. Kao" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Endocrinol (Oxf)" "fecha" => "2015" "volumen" => "82" "paginaInicial" => "503" "paginaFinal" => "508" ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0450" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduced bone mass and muscle strength in male 5α-reductase type 1 inactivated mice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.H. Windahl" 1 => "N. Andersson" 2 => "A.E. Börjesson" 3 => "C. Swanson" 4 => "J. Svensson" 5 => "S. Movérare-Skrtic" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "PLoS One" "fecha" => "2011" "volumen" => "6" "paginaInicial" => "e21402" ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0455" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Giatti" 1 => "S. Diviccaro" 2 => "G. Panzica" 3 => "R.C. Melcangi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12020-018-1593-5" "Revista" => array:6 [ "tituloSerie" => "Endocrine" "fecha" => "2018" "volumen" => "61" "paginaInicial" => "180" "paginaFinal" => "193" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29675596" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0460" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D. Healy" 1 => "J. Le Noury" 2 => "D. Mangin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3233/JRS-180744" "Revista" => array:6 [ "tituloSerie" => "Int J Risk Saf Med" "fecha" => "2018" "volumen" => "29" "paginaInicial" => "125" "paginaFinal" => "134" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29733030" "web" => "Medline" ] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0465" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A comment on the post-finasteride syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "H.D. Rezende" 1 => "M.F.R.G. Dias" 2 => "R.M. Trüeb" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int J Trichol" "fecha" => "2018" "volumen" => "10" "paginaInicial" => "255" "paginaFinal" => "261" ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0470" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Investigation of the plausibility of 5-alpha-reductase inhibitor syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R. Fertig" 1 => "J. Shapiro" 2 => "W. Bergfeld" 3 => "A. Tosti" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Skin Appendage Disord" "fecha" => "2017" "volumen" => "2" "paginaInicial" => "120" "paginaFinal" => "129" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/03650596/0000009500000003/v4_202007210853/S0365059620300970/v4_202007210853/en/main.assets" "Apartado" => array:4 [ "identificador" => "80634" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Continuing Medical Education" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/03650596/0000009500000003/v4_202007210853/S0365059620300970/v4_202007210853/en/main.pdf?idApp=UINPBA00008Z&text.app=https://clinics.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059620300970?idApp=UINPBA00008Z"]

Estatísticas

Continuing Medical Education

Post-finasteride syndrome

Ana Francisca Junqueira Ribeiro Pereira

Autor para correspondência

anafranciscadermato@gmail.com

Corresponding author.

, Thaissa Oliveira de Almeida Coelho

Trichology Outpatient Clinic, Dermatology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Lido

14873

Vezes
que se leu este artigo

3705

Total PDF

11168

Total HTML

Compartilhar estatísticas

 array:22 [
  "pii" => "S0365059620300970"
  "issn" => "03650596"
  "doi" => "10.1016/j.abd.2020.02.001"
  "estado" => "S300"
  "fechaPublicacion" => "2020-05-01"
  "aid" => "186"
  "copyrightAnyo" => "2020"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by/4.0/"
  "subdocumento" => "fla"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "pt" => array:18 [
      "pii" => "S266627522030165X"
      "issn" => "26662752"
      "doi" => "10.1016/j.abdp.2020.02.001"
      "estado" => "S300"
      "fechaPublicacion" => "2020-05-01"
      "aid" => "186"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by/4.0/"
      "subdocumento" => "fla"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "pt" => array:11 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Educa&#231;&#227;o m&#233;dica continuada</span>"
        "titulo" => "S&#237;ndrome p&#243;s&#8208;finasterida"
        "tienePdf" => "pt"
        "tieneTextoCompleto" => "pt"
        "tieneResumen" => "pt"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "271"
            "paginaFinal" => "277"
          ]
        ]
        "contieneResumen" => array:1 [
          "pt" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "pt" => true
        ]
        "contienePdf" => array:1 [
          "pt" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Ana Francisca Junqueira Ribeiro Pereira, Thaissa Oliveira de Almeida Coelho"
            "autores" => array:2 [
              0 => array:2 [
                "nombre" => "Ana Francisca Junqueira Ribeiro"
                "apellidos" => "Pereira"
              ]
              1 => array:2 [
                "nombre" => "Thaissa Oliveira de Almeida"
                "apellidos" => "Coelho"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "pt"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S0365059620300970"
          "doi" => "10.1016/j.abd.2020.02.001"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059620300970?idApp=UINPBA00008Z"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S266627522030165X?idApp=UINPBA00008Z"
      "url" => "/26662752/0000009500000003/v1_202006250813/S266627522030165X/v1_202006250813/pt/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S0365059620300933"
    "issn" => "03650596"
    "doi" => "10.1016/j.abd.2019.09.028"
    "estado" => "S300"
    "fechaPublicacion" => "2020-05-01"
    "aid" => "182"
    "copyright" => "Sociedade Brasileira de Dermatologia"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "fla"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Investigation</span>"
      "titulo" => "Immunostaining study of cytokeratins in human hair follicle development"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "278"
          "paginaFinal" => "282"
        ]
      ]
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1034
              "Ancho" => 1500
              "Tamanyo" => 307946
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Cytokeratin&#39;s immunostaining in human hair follicle development&#46; &#40;A&#41; CK1 immunoexpression at 19 weeks fetus&#46; &#40;B&#41; CK14 immunoexpression at 12 weeks fetus&#46; &#40;C&#41; CK20 immunoexpression at 21 weeks fetus&#46; &#40;D&#41; CK16 immunoexpression at 12 weeks fetus&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Laura Maria Andrade Silva, Ricardo Hsieh, Silvia Vanessa Louren&#231;o, Neusa Yuriko Sakai Valente, Geise Rezende Paiva, Juliana Dumet Fernandes"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "Laura Maria Andrade"
              "apellidos" => "Silva"
            ]
            1 => array:2 [
              "nombre" => "Ricardo"
              "apellidos" => "Hsieh"
            ]
            2 => array:2 [
              "nombre" => "Silvia Vanessa"
              "apellidos" => "Louren&#231;o"
            ]
            3 => array:2 [
              "nombre" => "Neusa Yuriko Sakai"
              "apellidos" => "Valente"
            ]
            4 => array:2 [
              "nombre" => "Geise Rezende"
              "apellidos" => "Paiva"
            ]
            5 => array:2 [
              "nombre" => "Juliana Dumet"
              "apellidos" => "Fernandes"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "pt" => array:9 [
        "pii" => "S2666275220301648"
        "doi" => "10.1016/j.abdp.2019.09.012"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "pt"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275220301648?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059620300933?idApp=UINPBA00008Z"
    "url" => "/03650596/0000009500000003/v4_202007210853/S0365059620300933/v4_202007210853/en/main.assets"
  ]
  "en" => array:18 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Continuing Medical Education</span>"
    "titulo" => "Post-finasteride syndrome"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "271"
        "paginaFinal" => "277"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Ana Francisca Junqueira Ribeiro Pereira, Thaissa Oliveira de Almeida Coelho"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "Ana Francisca Junqueira Ribeiro"
            "apellidos" => "Pereira"
            "email" => array:1 [
              0 => "anafranciscadermato@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "&#42;"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:2 [
            "nombre" => "Thaissa Oliveira de Almeida"
            "apellidos" => "Coelho"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Trichology Outpatient Clinic&#44; Dermatology Service&#44; Hospital das Cl&#237;nicas&#44; Universidade Federal de Minas Gerais&#44; Belo Horizonte&#44; MG&#44; Brazil"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Finasteride is an inhibitor of the enzyme 5&#945;-reductase types 1 and 2 &#8211; with greater affinity for type 2 &#8211; that has been approved by the Food and Drug Administration &#40;FDA&#41; in the United States for the treatment of benign prostatic hyperplasia &#40;BPH&#41; since 1992 and for the treatment of male androgenetic alopecia &#40;AGA&#41; since 1997&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">With a short half-life ranging from 4&#46;7 to 7&#46;1<span class="elsevierStyleHsp" style=""></span>h&#44;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">1</span></a> it is able to significantly reduce serum&#44; prostatic&#44; and scalp levels of dihydrotestosterone &#40;DHT&#41;&#44; in addition to slightly raising testosterone levels&#44;<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">2</span></a> generally without exceeding the reference values for the latter&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Over time&#44; several studies have demonstrated that finasteride is a safe and well-tolerated drug&#44; with rare and reversible side effects such as reduced sexual libido and ejaculatory volume&#44; most commonly observed when prescribed in a daily dose of 5<span class="elsevierStyleHsp" style=""></span>mg for cases of BPH&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">1</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">However&#44; reports of adverse reactions related to finasteride that persisted for at least three months after its discontinuation have emerged in the past decade&#46; The term post-finasteride syndrome &#40;PFS&#41; includes persistent sexual&#44; neuropsychiatric&#44; and physical adverse reactions in patients who used this drug&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">As a result&#44; regulatory agencies in several countries generated warnings about this drug&#59; in 2012&#44; the FDA demanded changes in the package insert in the United States&#44; including the possibility of persistent side effects&#46;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">3</span></a> In 2015&#44; PFS was included in the list of Rare and Genetic Diseases of the National Institutes of Health &#40;NIH&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">4</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Symptoms of PFS include decrease or complete loss of libido&#44; low or no reaction to sexual stimulation&#44; erectile dysfunction&#44; loss of pleasure or absence of sensation in orgasm&#44; loss of genital sensitivity&#44; decrease in ejaculated volume&#44; poor semen quality and infertility&#44; penis shrinkage&#44; abnormal penis curvature &#40;Peyronie&#39;s disease&#41;&#44; testicular pain&#44; testicular reduction&#44; gynecomastia&#44; chronic fatigue&#44; muscle weakness&#44; muscle atrophy and&#47;or pain&#44; muscle spasms&#44; joint pain&#44; dry skin&#44; memory problems&#44; slow thinking&#44; comprehension difficulties&#44; depression &#40;including suicidal thoughts&#41;&#44; anxiety disorder&#44; panic attacks&#44; emotional detachment&#44; and insomnia&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">5</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Finasteride and sexual adverse effects</span><p id="par0035" class="elsevierStylePara elsevierViewall">Albeit uncommon&#44; sexual dysfunction secondary to finasteride use is a known adverse effect that involves loss of libido&#44; in addition to erectile and ejaculatory disorders&#46; More recently&#44; sexual anhedonia&#44; changes in the structure of the penis&#44; and reduced penile sensitivity have also been reported&#46; However&#44; the persistence of these symptoms after the discontinuation of the drug is still a matter of controversy in the scientific community&#59; to date&#44; there are no studies that adequately assess this issue&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">After 15 years of FDA approval of the use of finasteride for AGA&#44; in a retrospective study&#44; Irwig et al&#46; interviewed 71 men who reported persistent sexual side effects after three months of discontinuing the drug&#44; which was used for AGA treatment at a daily dose of 1<span class="elsevierStyleHsp" style=""></span>mg&#44; with a mean use of 28 weeks and mean symptom duration of 40 weeks&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">6</span></a> However&#44; these patients were selected primarily in an online discussion forum aimed at individuals with sexual complaints after the use of 5&#945;-reductase inhibitors&#44; which constitutes an important selection bias&#46; After 14 months&#44; the same authors re-interviewed these patients&#44; and 89&#37; still reported adverse sexual effects&#46;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">7</span></a> Another retrospective study&#44; conducted in 2016&#44; of 79 individuals who received finasteride at a daily dose of 1<span class="elsevierStyleHsp" style=""></span>mg for a mean of 27 months and developed long-lasting adverse effects&#44; demonstrated persistence of symptoms for almost four years after treatment discontinuation&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">8</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">These findings&#44; however&#44; are in contrast with previous studies that demonstrated the safety of finasteride&#46; In 2003&#44; a large double-blinded placebo-controlled clinical trial assessed the incidence of sexual side effects with the use of finasteride at a daily dose of 5<span class="elsevierStyleHsp" style=""></span>mg&#46;<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">9</span></a> Among patients who discontinued the drug due to sexual dysfunction&#44; the persistence of symptoms was greater in the placebo group when compared with the treatment group&#44; suggesting that the drug was probably not involved in the persistence of the complaints&#46;<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">9</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Two recent meta-analyses that assessed the incidence of sexual adverse effects did not directly address the persistence of symptoms&#46;<a class="elsevierStyleCrossRefs" href="#bib0285"><span class="elsevierStyleSup">10&#44;11</span></a> A systematic review and meta-analysis conducted in 2016 observed a significantly greater risk of sexual dysfunction among patients with BPH&#44; but not in those undergoing AGA treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">10</span></a> The two divergent factors between the two groups that probably influenced these findings were the mean age and the daily dose used for each disease&#46; Moreover&#44; persistent symptoms were not evaluated&#46; Conflicting results were found by another 2019 meta-analysis&#44; which identified a two-fold increased risk of sexual dysfunction with the use of finasteride to treat AGA when compared with placebo&#46;<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">11</span></a> However&#44; the persistence of symptoms was also not analyzed in the included studies&#44; and remains unclear&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">In this sense&#44; a randomized double-blinded study with 117 men assessed persistent sexual side effects in patients allocated to dutasteride or placebo&#46;<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">12</span></a> During its use&#44; the incidence of sexual adverse reactions was twice as high in the dutasteride group&#44; and symptom onset occurred primarily in the first three months of treatment&#46; However&#44; most symptoms were resolved during treatment&#59; those that persisted were resolved within three to six weeks after treatment discontinuation&#46;<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">12</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">In contrast&#44; a 2017 retrospective cohort involving 4284 men aged 16 to 42 years who used finasteride at a daily dose of less than 1&#46;25<span class="elsevierStyleHsp" style=""></span>mg&#44; with a median of 4 years after suspension&#44; observed a rate of 0&#46;8&#37; of persistent sexual symptoms&#46;<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">13</span></a> Of the 103 men who experienced sexual symptoms during treatment&#44; 33&#37; reported they persisted after suspension&#46; The main independent predictor was use for a period longer than seven months&#46;<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">13</span></a> This finding is in agreement with data from the previous retrospective study by Irwig et al&#46;&#44; in which the onset of symptoms in patients with persistent complaints occurred after one year of using finasteride&#44; although few had reported adverse effects in the first month of use&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">6</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">Therefore&#44; the current literature data are controversial&#44; and it is not yet possible to establish a causal relationship between 5&#945;-reductase inhibitors and the persistence of sexual symptoms&#46; The studies that demonstrated a higher incidence of persistent side effects related to the use of finasteride have important biases and included limited samples&#44; and are insufficient to confirm the existence of PFS&#46; Likewise&#44; they also do not allow distinguishing between a real adverse effect or a nocebo reaction to the medication&#46; This nocebo effect was well documented in a study comparing patients who received counseling prior to finasteride treatment regarding the possibility of sexual side effects and those who had not&#59; 43&#46;6&#37; of the patients who were informed presented symptoms&#44; compared with 15&#46;3&#37; of the other group&#46;<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">14</span></a> The nocebo effect may also be related to the occurrence of persistent sexual complaints&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">Men with persistent sexual symptoms after discontinuation of finasteride for AGA did not present a corresponding hormonal dysfunction&#44; with maintenance of normal serum levels of testosterone and DHT&#44; nor did they show loss of peripheral sensitivity to androgens or permanent inhibition of androgen receptors&#46;<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">15</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">In order to elucidate the pathophysiology of PFS&#44; animal studies were carried out and suggested changes in penile histology and architecture after the use of 5&#945;-reductase inhibitors&#44; with a decrease in smooth muscle and an increase in collagen in the penis after treatment with dutasteride&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">16</span></a> A human study compared the histological foreskin findings in individuals with permanent sexual symptoms six months after finasteride withdrawal and found a difference in androgen receptor density when compared with those without prior exposure to 5&#945;-reductase inhibitors&#44;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">17</span></a> but the data were not compared to those of previous users without persistent symptoms&#46; Although these were small studies&#44; they provide histological evidence of potentially permanent penile structural changes after the use of 5&#945;-reductase inhibitors&#46; However&#44; it is not possible to establish a causal relationship between the findings or to draw definitive conclusions about their clinical significance&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Finasteride and infertility</span><p id="par0080" class="elsevierStylePara elsevierViewall">The impact of 5&#945;-reductase inhibitors on male fertility is another topic of debate&#46; In two different analyses by Samplaski et al&#46; with populations of men who sought treatment at infertility clinics&#44; only 0&#46;6&#37; and 0&#46;9&#37; of them were finasteride users&#44; from a total of 4400 and 4287 individuals&#44; respectively&#46;<a class="elsevierStyleCrossRefs" href="#bib0325"><span class="elsevierStyleSup">18&#44;19</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">Researchers had previously demonstrated a negative impact of finasteride on the spermatogenesis of rats&#46;<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">20</span></a> However&#44; Overstreet et al&#46; found that finasteride at a daily dose of 1<span class="elsevierStyleHsp" style=""></span>mg did not alter spermatogenesis&#44; semen production&#44; or sperm morphology in healthy young men&#46;<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">21</span></a> This was the largest randomized&#44; controlled&#44; double-blinded study on the impact of using 1<span class="elsevierStyleHsp" style=""></span>mg finasteride on spermatogenesis&#44; assessing 79 patients without any reproductive system alterations or history of infertility&#46; The results showed no change in semen volume or sperm concentration and motility after 48 weeks of using the drug&#46; Subjects were reassessed 60 weeks after discontinuation&#44; and no relevant changes were observed&#44; except for a recovery in prostate volume&#44; which was reduced during treatment&#46; Likewise&#44; no changes in gonadotropin or testosterone levels were detected&#46; Testosterone&#44; not DHT&#44; appears to be the main androgen regulating spermatogenesis&#46;<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">21</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">Glina et al&#46; reported three cases of young patients with semen quality disorders during treatment with finasteride&#46;<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">22</span></a> All three patients presented abnormal concentration and altered sperm motility when using finasteride at a daily dose of 1<span class="elsevierStyleHsp" style=""></span>mg&#46; These changes were completely reversed &#40;patients 1 and 2&#41; or improved &#40;patient 3&#41; three or four months after treatment interruption&#46; Two patients had varicocele on the left and the other was obese&#44; leading the researchers to suggest that finasteride does not markedly alter the spermatogenesis process in healthy men&#44; but in patients with infertility-related conditions&#44; the negative effect of the drug could be amplified&#46;<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">22</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">Corroborating this hypothesis&#44; in the retrospective study by Samplaski et al&#46;&#44; conducted in 2013&#44; the impact of the same daily dose of 1<span class="elsevierStyleHsp" style=""></span>mg of finasteride on the sperm count of 14 men with a history of infertility was analyzed&#44; with a mean use of 57 months &#40;2&#8211;120 months&#41;&#44; and mean time from treatment interruption to repeat spermogram of 6&#46;45 months &#40;2&#8211;18 months&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">18</span></a> That study demonstrated an 11&#46;6-fold mean increase in sperm concentration after finasteride discontinuation&#46; In the first analysis&#44; seven of these patients presented critical sperm levels &#40;below 5<span class="elsevierStyleHsp" style=""></span>million&#47;mL&#41;&#44; reaching levels above 20<span class="elsevierStyleHsp" style=""></span>million&#47;mL after treatment interruption&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">18</span></a> There was also an increase in sperm motility&#44; but not statistically significant&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">18</span></a> This was the only study that assessed the impact on individuals with conditions that predisposed to infertility&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">Liu et al&#46; and Chiba et al&#46; reported cases of infertile patients with azoospermia or oligospermia who showed significant improvement in sperm concentration after discontinuation of finasteride at a dose of 1<span class="elsevierStyleHsp" style=""></span>mg&#59; those authors also suggested that the drug may aggravate cases of subfertility or infertility&#46;<a class="elsevierStyleCrossRefs" href="#bib0350"><span class="elsevierStyleSup">23&#44;24</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Other aspects that could affect spermatogenesis in finasteride users include a higher sperm DNA fragmentation rate&#44; demonstrated in a case report&#44;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">25</span></a> and an eventual epididymis dysfunction&#44; proposed in a study in rats<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">26</span></a>&#59; however&#44; none of these effects persisted after treatment was stopped&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">In 2007&#44; a multicenter&#44; randomized&#44; double-blinded study with 99 healthy men with normal sperm parameters compared the use of finasteride at a dose of 5<span class="elsevierStyleHsp" style=""></span>mg&#44; dutasteride 0&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#44; and placebo&#44; showing a mean reduction of 30&#37; in sperm count and 6&#8211;12&#37; in motility after six months in the finasteride and dutasteride groups&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">27</span></a> However&#44; after one year of using one of the drugs&#44; an improvement was observed in the sperm count&#59; the reduction only remained statistically significant in the dutasteride group&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">27</span></a> Regarding the persistent findings in the dutasteride group&#44; the reduction in sperm volume and count was maintained after six months of discontinuation of the drug&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">27</span></a> Both drugs were associated with loss of sperm motility six months after treatment suspension&#46; No alterations in sperm morphology were observed in any group&#46; The repercussion of the findings on spermatogenesis was below the level pre-established as critical by the researchers&#44; and the mean alterations observed would probably not have clinical significance in human reproduction&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">27</span></a> Only three of these patients were more sensitive to the drug and reached counts as low as 10&#37; of their baseline during treatment&#44; one of whom used finasteride and the other two&#44; dutasteride&#46; These more severe cases presented partial recovery six months after drug suspension&#46; The authors suggested the possibility of an individual variability in the response to 5&#945;-reductase inhibitors&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">27</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Finasteride and neuropsychiatric adverse effects</span><p id="par0115" class="elsevierStylePara elsevierViewall">Neuroactive steroids comprise steroid hormones synthesized in peripheral glands acting on the central nervous system &#40;CNS&#41;&#44; as well as neurosteroids produced in the brain itself&#46;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">28</span></a> The main neuroactive steroids are pregnenolone &#40;PREG&#41;&#44; dehydroepiandrosterone &#40;DHEA&#41;&#44; progesterone&#44; testosterone&#44; and 17&#946;-estradiol&#44; which have important physiological regulatory actions&#44; such as neuroendocrine control in reproduction and sexual behavior&#44; adjustment of synaptic plasticity&#44; and cytoskeletal protein regulation&#44; in addition to acting in the morphology of neurons and astrocytes&#44; in the myelin compartment&#44; in adult neurogenesis&#44; and in functions related to cognition&#46;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">28</span></a></p><p id="par0120" class="elsevierStylePara elsevierViewall">The three isoforms of 5&#945;-reductase have already been identified in the brain&#44; and the physiological role of type 3 of the enzyme is the most explored so far&#46;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">28</span></a> In the CNS&#44; progesterone and testosterone are metabolized by the enzyme 5&#945;-reductase into dehydroprogesterone &#40;DHP&#41; and DHT&#44; respectively&#44; which are soon converted into more metabolites&#44; such as tetrahydroprogesterone &#40;THP&#41;&#44; isopregnanolone&#44; 5&#945;-androstane-3&#945;&#44; 17&#946;-diol&#44; and 5&#945;-androstane-3&#946;&#44;17&#946;-diol&#44; whose action occurs through classic &#40;androgen&#44; estrogen&#44; and progestogen receptors&#41; and non-classic receptors &#40;GABA-A receptors&#41;&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">In the assessment of neuropsychiatric adverse effects related to 5&#945;-reductase inhibitors&#44; randomized controlled studies are lacking&#46; Pre-clinical studies have demonstrated a reduction in neurosteroid levels&#46; Of the clinical studies&#44; very few are prospective&#59; the remaining literature is restricted to case reports&#44; reporting depression and anxiety without association with sexual dysfunction in finasteride users&#44; with improvement in symptoms after drug discontinuation and early recurrence of symptoms with treatment reinitiation&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">29</span></a> Persistent symptoms were reported in only three retrospective studies&#46; One of them&#44; conducted in 2011 without a control group&#44; reported complaints of depression&#44; suicidal ideation&#44; and persistent sexual symptoms in former finasteride users&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">6</span></a> In 2015&#44; Ganzer et al&#46; assessed 131 individuals with persistent complaints&#44; most of whom&#44; unusually&#44; started to present symptoms after the medication was discontinued&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">5</span></a> At the same time&#44; a pharmacovigilance study identified 4910 reports of persistent symptoms related to finasteride over 15 years&#46;<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">30</span></a> Among them&#44; there were 39 cases &#40;0&#46;79&#37;&#41; of suicidal ideation&#44; and 34 of these patients also had persistent erectile dysfunction&#46;<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">30</span></a> Thus&#44; it was not possible to determine whether suicidal ideation is associated with finasteride and&#47;or with the concomitant sexual disorders&#46;<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">30</span></a></p><p id="par0130" class="elsevierStylePara elsevierViewall">Persistent changes in neuroactive steroids have been documented in rodent brains after finasteride discontinuation&#46;<a class="elsevierStyleCrossRef" href="#bib0390"><span class="elsevierStyleSup">31</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">A prospective multicenter longitudinal clinical study conducted in 2017 observed abnormalities in plasma levels and cerebrospinal fluid &#40;CSF&#41; of neuroactive steroids in individuals with persistent symptoms after finasteride suspension&#46;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">28</span></a> The case group was formed by healthy men aged between 22 and 44 years who used 1&#8211;1&#46;25<span class="elsevierStyleHsp" style=""></span>mg of finasteride daily&#44; suspended for at least three months&#44; and who did not use other drugs with potential side effects&#44; nor had a history of depression or sexual dysfunction&#46; A total of 16 individuals with PFS were recruited&#44; with 14 remaining at the end of the study&#44; of whom 11 had their hormones levels measured in blood and CSF &#40;PREG&#44; progesterone&#44; DHEA&#44; DHP&#44; DHT&#44; testosterone&#44; THP&#44; isopregnenolone&#44; 17&#946;-estradiol&#44; 3&#945;- and 3&#946;-diol&#41;&#44; in addition to 25 controls&#46; The levels of PREG&#44; as well as progesterone and DHP&#44; were significantly reduced in the CSF of patients with PFS&#44; and those of DHEA and testosterone significantly elevated&#44; with a reduction in DHT and 17&#946;-estradiol&#46; In plasma&#44; an increase in DHEA and testosterone was also observed&#44; but PREG was very high&#46;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">28</span></a> That study presents as a bias the fact that patients were recruited through a website aimed at men with complaints related to finasteride&#46; It was concluded that finasteride not only affects the levels of 5&#945;-reduced metabolites of progesterone and testosterone&#44; as would be expected&#44; but also changes other metabolites and precursors&#44; suggesting that this has a wider consequence in the levels of neuroactive steroids in patients with PFS&#46;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">28</span></a> Of the 16 PFS patients in this study&#44; eight had major depression&#46; The hypothesis that testosterone levels may not be predictive of erectile dysfunction or depression&#44; but rather DHT levels&#44; was raised&#59; a possible association between reduced progesterone levels and depressive symptoms was suggested&#46; The possibility that erectile dysfunction is related to peripheral neuropathy was also raised&#44; since those authors also observed a reduction in the evoked potential of the pudendal nerve&#46;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">28</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">A 2019 study detected&#44; even after drug discontinuation&#44; a reduction in progesterone levels and their corresponding metabolites &#8211; DHP and THP &#8211; and an increase in its precursor PREG&#44; in addition to a drastic drop in the level of DHT and an increase in CSF testosterone&#46;<a class="elsevierStyleCrossRef" href="#bib0395"><span class="elsevierStyleSup">32</span></a> In plasma&#44; a reduction in DHP and 17&#946;-estradiol was observed&#46; In conclusion&#44; the authors indicated that previous sexual and&#47;or psychological conditions would lead to a greater risk and magnitude of adverse reactions to finasteride&#44; and it is important to assess sexual dysfunction and psychiatric disorders before starting the medication&#46;<a class="elsevierStyleCrossRef" href="#bib0395"><span class="elsevierStyleSup">32</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">Following this same idea&#44; in 2018&#44; a study included 97 men aged 18 years or older who reported persistent adverse effects after using finasteride at a daily dose of 1<span class="elsevierStyleHsp" style=""></span>mg for at least three months&#44; excluding those with basic sexual dysfunction and non-confirmed psychiatric diagnosis&#46;<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">33</span></a> Of the participants&#44; 55&#37; had had a psychiatric diagnosis prior to the use of finasteride and 28&#46;8&#37; had a history of psychiatric diagnosis in a first-degree relative&#59; 11&#46;3&#37; had both&#46; After discontinuing the drug&#44; 34&#37; reported anxiety and 49&#46;3&#37; depression&#59; in 79&#46;2&#37; of those with depression&#44; the condition was classified as moderate to severe&#44; and in 10&#46;4&#37;&#44; as severe&#46;<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">33</span></a> The researchers also reinforced the need for screening for a previous psychiatric history and counseling on the potential psychological consequences of using finasteride in predisposed individuals&#44; weighing the risks and benefits of treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">33</span></a></p><p id="par0150" class="elsevierStylePara elsevierViewall">A retrospective study conducted in 2016 with 79 men aged 18 to 50 years old demonstrated anhedonia as the most frequent non-sexual symptom&#44; occurring in 75&#46;9&#37; of patients&#59; 72&#46;2&#37; complained of difficulty in focusing&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">8</span></a> In addition to the small sample&#44; it is important to note the selection bias of that study&#44; since subjects were invited to participate after having answered a survey on a PFS-awareness website&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall">In turn&#44; it is important to remember that the studies carried out so far do not allow establishing a causal relationship between symptoms and the use of finasteride&#44; and the prevalence of these events has not been calculated&#46;<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">34</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Finasteride and metabolic and cardiovascular events</span><p id="par0160" class="elsevierStylePara elsevierViewall">By altering steroid metabolism&#44; 5&#945;-reductase inhibitors may contribute to insulin resistance&#44;<a class="elsevierStyleCrossRefs" href="#bib0410"><span class="elsevierStyleSup">35&#8211;39</span></a> increasing the predisposition to diabetes&#44; hepatic steatosis&#44;<a class="elsevierStyleCrossRefs" href="#bib0425"><span class="elsevierStyleSup">38&#44;40</span></a> alteration of body fat distribution&#44;<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">37&#44;38</span></a> metabolic syndrome&#44; and cardiovascular diseases&#44; since they reduce the clearance of glucocorticoids and mineralocorticoids&#46;<a class="elsevierStyleCrossRef" href="#bib0415"><span class="elsevierStyleSup">36</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">In a study of metabolic dysfunction in patients treated with finasteride or dutasteride compared with controls&#44; inhibition of both isoforms &#40;1 and 2&#41; of the enzyme 5&#945;-reductase by dutasteride was associated with higher peripheral insulin levels&#46;<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">41</span></a></p><p id="par0170" class="elsevierStylePara elsevierViewall">A preclinical study corroborated these findings&#46; The absence of type 1 isoenzyme 5&#945;-reductase was associated&#44; in rats&#44; with hepatic steatosis&#44; insulin resistance&#44; and changes in the distribution of body fat&#46;<a class="elsevierStyleCrossRef" href="#bib0425"><span class="elsevierStyleSup">38</span></a></p><p id="par0175" class="elsevierStylePara elsevierViewall">The metabolic implications would be more significant with dutasteride&#44; but more clinical studies are needed to confirm such effects in users of 5&#945;-reductase inhibitors&#46; It is also important to discuss screening for metabolic syndrome and insulin resistance in 5&#945;-reductase inhibitors candidates over 35 years of age with risk factors&#44; which may account for over half of the candidates&#46;<a class="elsevierStyleCrossRef" href="#bib0410"><span class="elsevierStyleSup">35</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">With regard to the risk of cardiovascular damage&#44; to date such have not been assessed with outcomes in clinical studies&#44;<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">37</span></a> hindering the determination of a causal relationship between the findings&#46; To date&#44; the information on this subject is limited&#44; since the relevant variables have not been analyzed in most studies&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">39</span></a></p><p id="par0185" class="elsevierStylePara elsevierViewall">Even bone metabolism may be altered&#44;<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">37&#44;42</span></a> and a case&#8211;control study recently demonstrated an increased risk of osteoporosis in finasteride users at a daily dose of 5<span class="elsevierStyleHsp" style=""></span>mg&#44; with evidence that it is a dose-dependent risk&#46;<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">42</span></a> The association between use of a 5&#945;-reductase inhibitor and loss of bone density and muscle strength was also suggested in an animal model&#44; in a study conducted in 2011 by Windahl et al&#46;<a class="elsevierStyleCrossRef" href="#bib0450"><span class="elsevierStyleSup">43</span></a>&#59; however&#44; these are preliminary data&#44; and there is still no strong enough evidence to support a prior bone density assessment in finasteride candidates&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Final considerations</span><p id="par0190" class="elsevierStylePara elsevierViewall">Despite all the doubts and fears raised by the reports in the last years&#44; finasteride is still considered a safe drug&#46; The aforementioned pharmacovigilance study conducted in 2015 collected few reports of persistent side effects related to the drug over 15 years&#59; nonetheless&#44; it is not possible to establish a causal relationship with the drug in many cases&#44; since other disorders were present&#46;<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">30</span></a></p><p id="par0195" class="elsevierStylePara elsevierViewall">In 2016&#44; Arias-Santiago et al&#46; raised the hypothesis of nocebo effect&#44; discussing whether the cause of the adverse effects of finasteride was more psychological than pharmacological&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">39</span></a> The authors also highlighted the emotional impact and self-esteem problems that AGA itself would cause&#44; and that this would serve as a confounding factor in the assessment of the occurrence of psychiatric and sexual symptoms in finasteride users&#46; However&#44; those authors observed that lower levels of certain steroid hormones could explain the symptoms reported in the literature&#44; even suggesting the use of a lower daily dose of finasteride in patients concerned about side effects&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">39</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">In the future&#44; the measurement of dopamine and serotonin levels in individuals with PFS may elucidate many issues&#44; since the pathways of these neurotransmitters can be altered in neurosteroidogenesis disorders&#44; which in itself would affect sexual behavior in these patients&#46;<a class="elsevierStyleCrossRef" href="#bib0455"><span class="elsevierStyleSup">44</span></a></p><p id="par0205" class="elsevierStylePara elsevierViewall">The possibility that epigenetic mechanisms may influence the occurrence of PFS is also discussed&#44; as it appears to affect a limited number of individuals exposed to the drug&#46;<a class="elsevierStyleCrossRef" href="#bib0455"><span class="elsevierStyleSup">44</span></a> Giatti et al&#46; even raised the hypothesis that PFS has mechanisms in common with post-selective serotonin reuptake inhibitor syndrome&#44; given the wide range of similar symptoms in the two clinical entities&#46;<a class="elsevierStyleCrossRef" href="#bib0455"><span class="elsevierStyleSup">44</span></a></p><p id="par0210" class="elsevierStylePara elsevierViewall">Finally&#44; it is difficult to discriminate which physiological&#44; endocrine&#44; or neurological aspects are primary or secondary&#44; and it is necessary to review the causality algorithms and to further analyze specific groups of patients&#44; assessing each history in more detail&#44; excluding the use of other drugs or relevant comorbidities&#44; for example&#46;<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">45</span></a></p><p id="par0215" class="elsevierStylePara elsevierViewall">It is noteworthy that the prevalence and incidence of persistent adverse reactions to finasteride has never been established and that PFS is not yet fully recognized by the scientific community&#46;<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">46&#44;47</span></a> Despite its homogeneous and characteristic symptoms&#44; the literature to date has low scientific quality&#44; which does not allow refuting or confirming PFS as a nosological entity&#59; however&#44; it should not be ignored&#46; If it does exist&#44; it appears to occur in susceptible individuals exposed even to small doses and for a short period&#44; whose symptoms may persist for a long time&#46;<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">34</span></a></p><p id="par0220" class="elsevierStylePara elsevierViewall">Therefore&#44; it is important to create practical recommendations in relation to patients&#8217; eligibility for treatment with finasteride&#44; as well as advising these individuals on possible risks&#44; alternative drugs for the treatment of AGA&#44; and how they should proceed in case of side effects&#46;<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">37&#44;43</span></a></p><p id="par0225" class="elsevierStylePara elsevierViewall">From the currently available data&#44; the use of 5&#945;-reductase inhibitors in individuals with a previous history of depression&#44; sexual dysfunction&#44; or infertility should be carefully assessed&#44; and the decision should be individualized&#46; Topical finasteride has been widely studied and may become a future alternative in the treatment of AGA&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Financial support</span><p id="par0230" class="elsevierStylePara elsevierViewall">None declared&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Authors&#39; contributions</span><p id="par0235" class="elsevierStylePara elsevierViewall">Ana Francisca Junqueira Ribeiro Pereira&#58; Approval of the final version of the manuscript&#59; elaboration and writing of the manuscript&#59; critical review of the literature&#59; critical review of the manuscript&#46;</p><p id="par0240" class="elsevierStylePara elsevierViewall">Thaissa Oliveira de Almeida Coelho&#58; Approval of the final version of the manuscript&#59; elaboration and writing of the manuscript&#59; critical review of the literature&#59; critical review of the manuscript&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Conflicts of interest</span><p id="par0245" class="elsevierStylePara elsevierViewall">None declared&#46;</p></span><p id="par9020" class="elsevierStylePara elsevierViewall"><elsevierMultimedia ident="tbl0140"></elsevierMultimedia></p><p id="par9021" class="elsevierStylePara elsevierViewall"><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></p></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres1365088"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1254920"
          "titulo" => "Keywords"
        ]
        2 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        3 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Finasteride and sexual adverse effects"
        ]
        4 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Finasteride and infertility"
        ]
        5 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Finasteride and neuropsychiatric adverse effects"
        ]
        6 => array:2 [
          "identificador" => "sec0025"
          "titulo" => "Finasteride and metabolic and cardiovascular events"
        ]
        7 => array:2 [
          "identificador" => "sec0030"
          "titulo" => "Final considerations"
        ]
        8 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Financial support"
        ]
        9 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Authors&#39; contributions"
        ]
        10 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Conflicts of interest"
        ]
        11 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2020-02-11"
    "fechaAceptado" => "2020-02-14"
    "PalabrasClave" => array:1 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1254920"
          "palabras" => array:3 [
            0 => "5-Alpha reductase inhibitors"
            1 => "Alopecia"
            2 => "Finasteride"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:1 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Finasteride is a 5&#945;-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997&#46; Over time&#44; it has been considered a safe and well-tolerated drug with rare and reversible side effects&#46; Recently there have been reports of adverse drug-related reactions that persisted for at least three months after discontinuation of this drug&#44; and the term post-finasteride syndrome arose&#46; It includes persistent sexual&#44; neuropsychiatric&#44; and physical symptoms&#46; Studies to date cannot refute or confirm this syndrome as a nosological entity&#46; If it actually exists&#44; it seems to occur in susceptible people&#44; even if exposed to small doses and for short periods&#44; and symptoms may persist for long periods&#46; Based on currently available data&#44; the use of 5&#945;-reductase inhibitors in patients with a history of depression&#44; sexual dysfunction&#44; or infertility should be carefully and individually assessed&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:2 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">How to cite this article&#58; Pereira AFJR&#44; Coelho TOA&#46; Post-finasteride syndrome&#46; An Bras Dermatol&#46; 2020&#59;95&#58;271&#8211;7&#46;</p>"
      ]
      1 => array:2 [
        "etiqueta" => "&#9734;&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Study conducted at the Trichology Outpatient Clinic&#44; Dermatology Service&#44; Hospital das Cl&#237;nicas&#44; Universidade Federal de Minas Gerais&#44; Belo Horizonte&#44; MG&#44; Brazil&#46;</p>"
      ]
    ]
    "multimedia" => array:2 [
      0 => array:5 [
        "identificador" => "tbl0140"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleBold">Questions EMC</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">1&#41; Regarding finasteride&#44; it is correct to state that&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">a&#41; It has a long half-life&#44; which could justify the reports of persistent adverse effects&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">b&#41; It is able to dramatically increase serum DHT and testosterone&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">c&#41; The occurrence of side effects related to the drug is not dose-dependent&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">d&#41; A few years ago&#44; a series of symptoms that appeared and even worsened after finasteride discontinuation have been attributed to the drug&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="1" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">2&#41; Check the incorrect alternative on adverse sexual effects in post-finasteride syndrome&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">a&#41; One of the main complaints is penile sensitivity reduction&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">b&#41; Symptoms of this syndrome are considered to be those that persist after three weeks of drug discontinuation&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">c&#41; Selection bias is the main limitation of studies that describe a higher incidence of these symptoms&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">d&#41; The duration of finasteride use appears to be a risk factor for the onset of the syndrome&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="1" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">3&#41; Regarding laboratory findings in individuals with post-finasteride syndrome&#44; it is possible to state that&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">a&#41; Serum testosterone levels are low and DHT levels are normal&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">b&#41; Serum DHT levels are low and testosterone levels are normal&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">c&#41; Serum testosterone and DHT levels are normal&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">d&#41; Serum testosterone and DHT levels are low&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="1" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">4&#41; In the pathophysiology of the persistent sexual effects of post-finasteride syndrome&#44; it can be stated that&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">a&#41; There is evidence of peripheral insensitivity to androgens&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">b&#41; Human studies suggest changes in penile histology and architecture&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">c&#41; There are signs of permanent inhibition of androgen receptors&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">d&#41; The nocebo effect cannot be ruled out in such cases&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="1" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">5&#41; Regarding finasteride and infertility&#44; it is correct to state that&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">a&#41; The drug is able to temporarily alter the sperm morphology&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">b&#41; The decrease in fertility does not appear to be related to the dose used&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">c&#41; There is a permanent reduction in the ejaculated volume&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">d&#41; There is still insufficient data to state that finasteride interferes with the spermatogenesis of healthy men&#44; without predisposing factors for infertility&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="1" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">6&#41; The following alterations in the spermogram secondary to the use of finasteride are possible&#44; except&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">a&#41; Oligospermia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">b&#41; Sperm DNA fragmentation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">c&#41; Aberrations in sperm morphology&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">d&#41; Reduction of sperm motility&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="1" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">7&#41; Regarding neurosteroid hormones&#44; it cannot be said that&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">a&#41; By definition&#44; these are hormones exclusively produced in the brain&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">b&#41; Examples of neurosteroid hormones are pregnenolone&#44; progesterone&#44; and testosterone&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">c&#41; In the central nervous system&#44; progesterone and testosterone are metabolized by the enzyme 5&#945;-reductase into&#44; respectively&#44; dihydroprogesterone and dihydrotestosterone&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">d&#41; The levels of brain metabolites of the 5&#945;-reductase enzyme are altered in degenerative and psychiatric diseases&#46;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="1" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">8&#41; Regarding post-finasteride syndrome it is correct to state that&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">a&#41; The possibility of a nocebo effect of the drug has already been ruled out&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">b&#41; The risk of depression and anxiety disorder in finasteride users is independent of the presence of a concomitant sexual disorder&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">c&#41; In the case of a personal history of underlying psychiatric illness&#44; the use of finasteride is not indicated&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">d&#41; Epigenetic mechanisms may explain the occurrence of the syndrome in only a limited number of individuals exposed to finasteride&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="1" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">9&#41; Regarding the metabolic effects of finasteride&#44; it is incorrect to state that&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">a&#41; The drug appears to contribute to peripheral insulin resistance and diabetes&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">b&#41; It changes the distribution of body fat and induces hepatic steatosis&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">c&#41; Due to its influence on bone metabolism&#44; a periodic bone density assessment in individuals using finasteride is mandatory&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">d&#41; Faced with a possible increase in cardiovascular risk&#44; more elaborate clinical studies that analyze countless relevant variables are necessary&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="1" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">10&#41; When assessing a patient with an indication for the use of finasteride&#44; the physician should consider&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">a&#41; Presence of previous psychiatric or sexual disorders&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">b&#41; Family history of psychiatric illnesses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">c&#41; Family history of infertility or subfertility&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">d&#41; Risk factors for metabolic syndrome&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="1" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2344590.png"
              ]
            ]
          ]
        ]
      ]
      1 => array:5 [
        "identificador" => "tbl0005"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleBold">Answers</span><span class="elsevierStyleBold">Use of psychiatric drugs in dermatology&#46; An Bras Dermatol&#46; 2020&#59;95&#40;2&#41;&#58;133-143</span>&#46;</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46; c&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46; c&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#46; a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#46; d&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&#46; a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46; c&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46; d&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#46; c&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#46; d&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&#46; b&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2344589.png"
              ]
            ]
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:47 [
            0 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Finasteride &#8211; an update and review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46;C&#46; Cather"
                            1 => "D&#46; Lane"
                            2 => "M&#46;R&#46; Heaphy Jr&#46;"
                            3 => "B&#46;R&#46; Nelson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cutis"
                        "fecha" => "1999"
                        "volumen" => "64"
                        "paginaInicial" => "167"
                        "paginaFinal" => "172"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10500917"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "5&#945;-Reductase&#58; history and clinical importance"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "L&#46;S&#46; Marks"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "Rev Urol"
                        "fecha" => "2004"
                        "volumen" => "6"
                        "numero" => "Suppl&#46; 9"
                        "paginaInicial" => "S11"
                        "paginaFinal" => "S21"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16985920"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Accessdata&#46;fda&#46;gov &#91;Internet&#93;&#46; Propecia &#40;finasteride&#41;&#46; Available from&#58; <a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process">https&#58;&#47;&#47;www&#46;accessdata&#46;fda&#46;gov&#47;scripts&#47;cder&#47;daf&#47;index&#46;cfm&#63;event&#61;BasicSearch&#46;process</a> &#91;cited 26&#46;10&#46;19&#93;&#46;"
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Rarediseases&#46;info&#46;nih&#46;gov &#91;Internet&#93;&#46; Adverse events of 5-alpha-reductase inhibitors&#46; Available from&#58; <a target="_blank" href="https://rarediseases.info.nih.gov/diseases/12407/post-finasteride-syndrome">https&#58;&#47;&#47;rarediseases&#46;info&#46;nih&#46;gov&#47;diseases&#47;12407&#47;post-finasteride-syndrome</a> &#91;cited 26&#46;10&#46;19&#93;&#46;"
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Persistent sexual&#44; emotional&#44; and cognitive impairment post-finasteride&#58; a survey of men reporting symptoms"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46;A&#46; Ganzer"
                            1 => "A&#46;R&#46; Jacobs"
                            2 => "F&#46; Iqbal"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1557988314538445"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Mens Health"
                        "fecha" => "2015"
                        "volumen" => "9"
                        "paginaInicial" => "222"
                        "paginaFinal" => "228"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24928450"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Persistent sexual side effects of finasteride for male pattern hair loss"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46;S&#46; Irwig"
                            1 => "S&#46; Kolukula"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1743-6109.2011.02255.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Sex Med"
                        "fecha" => "2011"
                        "volumen" => "8"
                        "paginaInicial" => "1747"
                        "paginaFinal" => "1753"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21418145"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Persistent sexual side effects of finasteride&#58; could they be permanent&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "M&#46;S&#46; Irwig"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1743-6109.2012.02846.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Sex Med"
                        "fecha" => "2012"
                        "volumen" => "9"
                        "paginaInicial" => "2927"
                        "paginaFinal" => "2932"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22789024"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "G&#46; Chiriac&#242;"
                            1 => "S&#46; Cauci"
                            2 => "G&#46; Mazzon"
                            3 => "C&#46; Trombetta"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Andrology"
                        "fecha" => "2016"
                        "volumen" => "4"
                        "paginaInicial" => "245"
                        "paginaFinal" => "250"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46; Wessells"
                            1 => "J&#46; Roy"
                            2 => "J&#46; Bannow"
                            3 => "J&#46; Grayhack"
                            4 => "A&#46;M&#46; Matsumoto"
                            5 => "L&#46; Tenover"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/s0090-4295(02)02401-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Urology"
                        "fecha" => "2003"
                        "volumen" => "61"
                        "paginaInicial" => "579"
                        "paginaFinal" => "584"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12639651"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of 5alpha-reductase inhibitors on sexual function&#58; a meta-analysis and systematic review of randomized controlled trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Liu"
                            1 => "S&#46; Zhao"
                            2 => "F&#46; Li"
                            3 => "E&#46; Li"
                            4 => "R&#46; Kang"
                            5 => "L&#46; Luo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jsxm.2016.07.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Sex Med"
                        "fecha" => "2016"
                        "volumen" => "13"
                        "paginaInicial" => "1297"
                        "paginaFinal" => "1310"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27475241"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Lee"
                            1 => "Y&#46;B&#46; Lee"
                            2 => "S&#46;J&#46; Choe"
                            3 => "W&#46;S&#46; Lee"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2340/00015555-3035"
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Derm Venereol"
                        "fecha" => "2019"
                        "volumen" => "99"
                        "paginaInicial" => "12"
                        "paginaFinal" => "17"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30206635"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46;F&#46; Tsai"
                            1 => "G&#46;S&#46; Choi"
                            2 => "B&#46;J&#46; Kim"
                            3 => "M&#46;B&#46; Kim"
                            4 => "C&#46;F&#46; Ng"
                            5 => "P&#46; Kochhar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/1346-8138.14329"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatol"
                        "fecha" => "2018"
                        "volumen" => "45"
                        "paginaInicial" => "799"
                        "paginaFinal" => "804"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29667763"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Persistent erectile dysfunction in men exposed to the 5alpha-reductase inhibitors&#44; finasteride&#44; or dutasteride"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Kiguradze"
                            1 => "W&#46;H&#46; Temps"
                            2 => "P&#46;R&#46; Yarnold"
                            3 => "J&#46; Cashy"
                            4 => "R&#46;E&#46; Brannigan"
                            5 => "B&#46; Nardone"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7717/peerj.3020"
                      "Revista" => array:5 [
                        "tituloSerie" => "PeerJ"
                        "fecha" => "2017"
                        "volumen" => "5"
                        "paginaInicial" => "e3020"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28289563"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Finasteride 5<span class="elsevierStyleHsp" style=""></span>mg and sexual side effects&#58; how many of these are related to a nocebo phenomenon&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "N&#46; Mondaini"
                            1 => "P&#46; Gontero"
                            2 => "G&#46; Giubilei"
                            3 => "G&#46; Lombardi"
                            4 => "T&#46; Cai"
                            5 => "A&#46; Gavazzi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1743-6109.2007.00563.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Sex Med"
                        "fecha" => "2007"
                        "volumen" => "4"
                        "paginaInicial" => "1708"
                        "paginaFinal" => "1712"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17655657"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Basaria"
                            1 => "R&#46; Jasuja"
                            2 => "G&#46; Huang"
                            3 => "W&#46; Wharton"
                            4 => "H&#46; Pan"
                            5 => "K&#46; Pencina"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1210/jc.2016-2726"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Endocrinol Metab"
                        "fecha" => "2016"
                        "volumen" => "101"
                        "paginaInicial" => "4669"
                        "paginaFinal" => "4680"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27662439"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Persistent erectile dysfunction after discontinuation of 5-alpha reductase inhibitor therapy in rats depending on the duration of treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46;H&#46; Sung"
                            1 => "J&#46; Yu"
                            2 => "S&#46;J&#46; Kang"
                            3 => "M&#46;R&#46; Chae"
                            4 => "I&#46; So"
                            5 => "J&#46;K&#46; Park"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.5534/wjmh.180082"
                      "Revista" => array:6 [
                        "tituloSerie" => "World J Mens Health"
                        "fecha" => "2019"
                        "volumen" => "37"
                        "paginaInicial" => "240"
                        "paginaFinal" => "248"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30588787"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "C&#46; Di Loreto"
                            1 => "F&#46; La Marra"
                            2 => "G&#46; Mazzon"
                            3 => "E&#46; Belgrano"
                            4 => "C&#46; Trombetta"
                            5 => "S&#46; Cauci"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0100237"
                      "Revista" => array:5 [
                        "tituloSerie" => "PLOS ONE"
                        "fecha" => "2014"
                        "volumen" => "9"
                        "paginaInicial" => "e100237"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24959691"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Finasteride use in the male infertility population&#58; effects on semen and hormone parameters"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46;K&#46; Samplaski"
                            1 => "K&#46; Lo"
                            2 => "E&#46; Grober"
                            3 => "K&#46; Jarvi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.fertnstert.2013.07.2000"
                      "Revista" => array:6 [
                        "tituloSerie" => "Fertil Steril"
                        "fecha" => "2013"
                        "volumen" => "100"
                        "paginaInicial" => "1542"
                        "paginaFinal" => "1546"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24012200"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Reproductive endocrinologists are the gatekeepers for male infertility care in North America&#58; results of a North American survey on the referral patterns and characteristics of men presenting to male infertility specialists for infertility investigations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;K&#46; Samplaski"
                            1 => "J&#46;F&#46; Smith"
                            2 => "K&#46;C&#46; Lo"
                            3 => "J&#46;M&#46; Hotaling"
                            4 => "S&#46; Lau"
                            5 => "E&#46;D&#46; Grober"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.fertnstert.2019.06.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Fertil Steril"
                        "fecha" => "2019"
                        "volumen" => "112"
                        "paginaInicial" => "657"
                        "paginaFinal" => "662"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31351700"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Testosterone-dependent restoration of spermatogenesis in adult rats is impaired by a 5alpha-reductase inhibitor"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "L&#46; O&#8217;Donnell"
                            1 => "K&#46; Pratis"
                            2 => "P&#46;G&#46; Stanton"
                            3 => "D&#46;M&#46; Robertson"
                            4 => "R&#46;I&#46; McLachlan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Androl"
                        "fecha" => "1999"
                        "volumen" => "20"
                        "paginaInicial" => "109"
                        "paginaFinal" => "117"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10100481"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;W&#46; Overstreet"
                            1 => "V&#46;L&#46; Fuh"
                            2 => "J&#46; Gould"
                            3 => "S&#46;S&#46; Howards"
                            4 => "M&#46;M&#46; Lieber"
                            5 => "W&#46; Hellstrom"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Urol"
                        "fecha" => "1999"
                        "volumen" => "162"
                        "paginaInicial" => "1295"
                        "paginaFinal" => "1300"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10492183"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0345"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Finasteride-associated male infertility"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "S&#46; Glina"
                            1 => "P&#46;A&#46; Neves"
                            2 => "R&#46; Saade"
                            3 => "N&#46;R&#46; Netto Jr&#46;"
                            4 => "J&#46;B&#46; Soares"
                            5 => "A&#46;G&#46; Galuppo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1590/s0041-87812004000400009"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Hosp Clin Fac Med Sao Paulo"
                        "fecha" => "2004"
                        "volumen" => "59"
                        "paginaInicial" => "203"
                        "paginaFinal" => "205"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15361986"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0350"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Propecia-induced spermatogenic failure&#58; a report of two cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "K&#46;E&#46; Liu"
                            1 => "S&#46; Binsaleh"
                            2 => "K&#46;C&#46; Lo"
                            3 => "K&#46; Jarvi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.fertnstert.2007.08.003"
                      "Revista" => array:5 [
                        "tituloSerie" => "Fertil Steril"
                        "fecha" => "2008"
                        "volumen" => "90"
                        "paginaInicial" => "849"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18625502"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Finasteride-associated male infertility"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "K&#46; Chiba"
                            1 => "K&#46; Yamaguchi"
                            2 => "F&#46; Li"
                            3 => "M&#46; Ando"
                            4 => "M&#46; Fujisawa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.fertnstert.2010.12.001"
                      "Revista" => array:5 [
                        "tituloSerie" => "Fertil Steril"
                        "fecha" => "2011"
                        "volumen" => "95"
                        "paginaInicial" => "1786"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21193189"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Finasteride-induced secondary infertility associated with sperm DNA damage"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "H&#46;Y&#46; Tu"
                            1 => "A&#46; Zini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.fertnstert.2011.01.025"
                      "Revista" => array:4 [
                        "tituloSerie" => "Fertil Steril"
                        "fecha" => "2011"
                        "volumen" => "95"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21292256"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0365"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Actions of 5alpha-reductase inhibitors on the epididymis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "B&#46; Robaire"
                            1 => "N&#46;A&#46; Henderson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Mol Cell Endocrinol"
                        "fecha" => "2006"
                        "volumen" => "250"
                        "paginaInicial" => "190"
                        "paginaFinal" => "195"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0370"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;K&#46; Amory"
                            1 => "C&#46; Wang"
                            2 => "R&#46;S&#46; Swerdloff"
                            3 => "B&#46;D&#46; Anawalt"
                            4 => "A&#46;M&#46; Matsumoto"
                            5 => "W&#46;J&#46; Bremner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Clin Endocrinol Metab"
                        "fecha" => "2007"
                        "volumen" => "92"
                        "paginaInicial" => "1659"
                        "paginaFinal" => "1665"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0375"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;C&#46; Melcangi"
                            1 => "D&#46; Santi"
                            2 => "R&#46; Spezzano"
                            3 => "M&#46; Grimoldi"
                            4 => "T&#46; Tabacchi"
                            5 => "M&#46;L&#46; Fusco"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jsbmb.2017.04.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Steroid Biochem Mol Biol"
                        "fecha" => "2017"
                        "volumen" => "171"
                        "paginaInicial" => "229"
                        "paginaFinal" => "235"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28408350"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0380"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Finasteride induced depression&#58; a prospective study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "B&#46; Rahimi-Ardabili"
                            1 => "R&#46; POurandarjani"
                            2 => "P&#46; Habibollahi"
                            3 => "A&#46; Mualeki"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1472-6904-6-7"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Clin Pharmacol"
                        "fecha" => "2006"
                        "volumen" => "6"
                        "paginaInicial" => "7"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17026771"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0385"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride&#58; a pharmacovigilance study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46;K&#46; Ali"
                            1 => "B&#46;S&#46; Heran"
                            2 => "M&#46; Etminan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/phar.1612"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pharmacotherapy"
                        "fecha" => "2015"
                        "volumen" => "35"
                        "paginaInicial" => "687"
                        "paginaFinal" => "695"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26133534"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0390"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of subchronic finasteride treatment and withdrawal on neuroactive steroid levels and their receptors in the male rat brain"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Giatti"
                            1 => "B&#46; Foglio"
                            2 => "S&#46; Romano"
                            3 => "M&#46; Pesaresi"
                            4 => "G&#46; Panzica"
                            5 => "L&#46;M&#46; Garcia-Segura"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000442982"
                      "Revista" => array:6 [
                        "tituloSerie" => "Neuroendocrinology"
                        "fecha" => "2016"
                        "volumen" => "103"
                        "paginaInicial" => "746"
                        "paginaFinal" => "757"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26646518"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0395"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Finasteride and androgenic alopecia&#59; from therapeutic options to medical implications"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46;G&#46; Motofei"
                            1 => "D&#46;L&#46; Rowland"
                            2 => "M&#46; Tampa"
                            3 => "M&#46;I&#46; Sarbu"
                            4 => "M&#46;I&#46; Mitran"
                            5 => "C&#46;I&#46; Mitran"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Dermatolog Treat"
                        "fecha" => "2019"
                        "volumen" => "21"
                        "paginaInicial" => "1"
                        "paginaFinal" => "7"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0400"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Emotional consequences of finasteride&#58; fool&#39;s gold"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "C&#46;A&#46; Ganzer"
                            1 => "A&#46;R&#46; Jacobs"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1557988316631624"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Mens Health"
                        "fecha" => "2018"
                        "volumen" => "12"
                        "paginaInicial" => "90"
                        "paginaFinal" => "95"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26868914"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0405"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Post-finasteride syndrome &#8211; does it really exist&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "R&#46;B&#46; Maksym"
                            1 => "A&#46; Kajdy"
                            2 => "M&#46; Rabijewski"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/13685538.2018.1548589"
                      "Revista" => array:6 [
                        "tituloSerie" => "Aging Male"
                        "fecha" => "2019"
                        "volumen" => "22"
                        "paginaInicial" => "250"
                        "paginaFinal" => "259"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30651009"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0410"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Changes of metabolic profile in men treated for androgenetic alopecia with 1<span class="elsevierStyleHsp" style=""></span>mg finasteride"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46; Duskova"
                            1 => "M&#46; Hill"
                            2 => "L&#46; Starka"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4149/endo_2010_01_3"
                      "Revista" => array:6 [
                        "tituloSerie" => "Endocr Regul"
                        "fecha" => "2010"
                        "volumen" => "44"
                        "paginaInicial" => "3"
                        "paginaFinal" => "8"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20151762"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0415"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "5&#945;-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance&#44; diabetes&#44; metabolic syndrome and vascular disease&#58; a medical hypothesis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46;M&#46; Traish"
                            1 => "A&#46;T&#46; Guay"
                            2 => "M&#46; Zitzmann"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1515/hmbci-2014-0025"
                      "Revista" => array:6 [
                        "tituloSerie" => "Horm Mol Biol Clin Investig"
                        "fecha" => "2014"
                        "volumen" => "20"
                        "paginaInicial" => "73"
                        "paginaFinal" => "80"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25460297"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0420"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adverse effects of 5&#945;-reductase inhibitors&#58; what do we know&#44; don&#8217;t know&#44; and need to know&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46;M&#46; Traish"
                            1 => "R&#46;C&#46; Melcangi"
                            2 => "M&#46; Bortolato"
                            3 => "L&#46;M&#46; Garcia-Segura"
                            4 => "M&#46; Zitzmann"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11154-015-9319-y"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Endocr Metab Disord"
                        "fecha" => "2015"
                        "volumen" => "16"
                        "paginaInicial" => "177"
                        "paginaFinal" => "198"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26296373"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0425"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "5&#945;-Reductase type 1 deficiency or inhibition predisposes to insulin resistance&#44; hepatic steatosis&#44; and liver fibrosis in rodents"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;E&#46; Livingstone"
                            1 => "P&#46; Barat"
                            2 => "E&#46;M&#46; Di Rollo"
                            3 => "G&#46;A&#46; Rees"
                            4 => "B&#46;A&#46; Weldin"
                            5 => "E&#46;A&#46; Rog-Zielinska"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2337/db14-0249"
                      "Revista" => array:6 [
                        "tituloSerie" => "Diabetes"
                        "fecha" => "2015"
                        "volumen" => "64"
                        "paginaInicial" => "447"
                        "paginaFinal" => "458"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25239636"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0430"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adverse effects of 5-alpha reductase inhibitor therapy in men with androgenetic alopecia&#58; is there cause for concern&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "S&#46; Arias-Santiago"
                            1 => "F&#46;M&#46; Camacho-Mart&#237;nez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2016.06.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2016"
                        "volumen" => "107"
                        "paginaInicial" => "709"
                        "paginaFinal" => "711"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27436801"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0435"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Dual-5&#945;-reductase inhibition promotes hepatic lipid accumulation in man"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Hazlehurst"
                            1 => "A&#46;I&#46; Oprescu"
                            2 => "N&#46; Nikolaou"
                            3 => "R&#46; Di Guida"
                            4 => "A&#46;E&#46; Grinbergs"
                            5 => "N&#46;P&#46; Davies"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Clin Endocrinol Metab"
                        "fecha" => "2016"
                        "volumen" => "101"
                        "paginaInicial" => "103"
                        "paginaFinal" => "113"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0440"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "5&#945;-Reductase type 1 modulates insulin sensitivity in men"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Upreti"
                            1 => "K&#46;A&#46; Hughes"
                            2 => "D&#46;E&#46; Livingstone"
                            3 => "C&#46;D&#46; Gray"
                            4 => "F&#46;C&#46; Minns"
                            5 => "D&#46;P&#46; Macfarlane"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Clin Endocrinol Metab"
                        "fecha" => "2014"
                        "volumen" => "99"
                        "paginaInicial" => "1397"
                        "paginaFinal" => "1406"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0445"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A population-based nested case&#8211;control study&#58; the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "W&#46;L&#46; Lin"
                            1 => "Y&#46;W&#46; Hsieh"
                            2 => "C&#46;L&#46; Lin"
                            3 => "F&#46;C&#46; Sung"
                            4 => "C&#46;H&#46; Wu"
                            5 => "C&#46;H&#46; Kao"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Endocrinol &#40;Oxf&#41;"
                        "fecha" => "2015"
                        "volumen" => "82"
                        "paginaInicial" => "503"
                        "paginaFinal" => "508"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0450"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Reduced bone mass and muscle strength in male 5&#945;-reductase type 1 inactivated mice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;H&#46; Windahl"
                            1 => "N&#46; Andersson"
                            2 => "A&#46;E&#46; B&#246;rjesson"
                            3 => "C&#46; Swanson"
                            4 => "J&#46; Svensson"
                            5 => "S&#46; Mov&#233;rare-Skrtic"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "PLoS One"
                        "fecha" => "2011"
                        "volumen" => "6"
                        "paginaInicial" => "e21402"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0455"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Post-finasteride syndrome and post-SSRI sexual dysfunction&#58; two sides of the same coin&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Giatti"
                            1 => "S&#46; Diviccaro"
                            2 => "G&#46; Panzica"
                            3 => "R&#46;C&#46; Melcangi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s12020-018-1593-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Endocrine"
                        "fecha" => "2018"
                        "volumen" => "61"
                        "paginaInicial" => "180"
                        "paginaFinal" => "193"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29675596"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0460"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Enduring sexual dysfunction after treatment with antidepressants&#44; 5&#945;-reductase inhibitors and isotretinoin&#58; 300 cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "D&#46; Healy"
                            1 => "J&#46; Le Noury"
                            2 => "D&#46; Mangin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3233/JRS-180744"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Risk Saf Med"
                        "fecha" => "2018"
                        "volumen" => "29"
                        "paginaInicial" => "125"
                        "paginaFinal" => "134"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29733030"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0465"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A comment on the post-finasteride syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "H&#46;D&#46; Rezende"
                            1 => "M&#46;F&#46;R&#46;G&#46; Dias"
                            2 => "R&#46;M&#46; Tr&#252;eb"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Int J Trichol"
                        "fecha" => "2018"
                        "volumen" => "10"
                        "paginaInicial" => "255"
                        "paginaFinal" => "261"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0470"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Investigation of the plausibility of 5-alpha-reductase inhibitor syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "R&#46; Fertig"
                            1 => "J&#46; Shapiro"
                            2 => "W&#46; Bergfeld"
                            3 => "A&#46; Tosti"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Skin Appendage Disord"
                        "fecha" => "2017"
                        "volumen" => "2"
                        "paginaInicial" => "120"
                        "paginaFinal" => "129"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/03650596/0000009500000003/v4_202007210853/S0365059620300970/v4_202007210853/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "80634"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Continuing Medical Education"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/03650596/0000009500000003/v4_202007210853/S0365059620300970/v4_202007210853/en/main.pdf?idApp=UINPBA00008Z&text.app=https://clinics.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059620300970?idApp=UINPBA00008Z"
]

Informação do artigo

ISSN: 03650596
Idioma original: Inglês

DOI:10.1016/j.abd.2020.02.001

Dados atualizados diariamente

Ano/Mês	Html	Pdf	Total

2024 Novembro	37	13	50
2024 Outubro	228	93	321
2024 Setembro	366	112	478
2024 Agosto	368	126	494
2024 Julho	285	137	422
2024 Junho	261	142	403
2024 Maio	309	67	376
2024 Abril	254	105	359
2024 Mar�o	187	82	269
2024 Fevereiro	258	79	337
2024 Janeiro	216	59	275
2023 Dezembro	254	72	326
2023 Novembro	262	120	382
2023 Outubro	260	102	362
2023 Setembro	251	97	348
2023 Agosto	449	60	509
2023 Julho	195	56	251
2023 Junho	237	55	292
2023 Maio	198	40	238
2023 Abril	194	51	245
2023 Mar�o	212	75	287
2023 Fevereiro	152	40	192
2023 Janeiro	154	85	239
2022 Dezembro	150	47	197
2022 Novembro	150	71	221
2022 Outubro	209	81	290
2022 Setembro	102	88	190
2022 Agosto	104	79	183
2022 Julho	125	72	197
2022 Junho	147	73	220
2022 Maio	93	64	157
2022 Abril	146	54	200
2022 Mar�o	93	65	158
2022 Fevereiro	80	49	129
2022 Janeiro	97	84	181
2021 Dezembro	82	73	155
2021 Novembro	66	61	127
2021 Outubro	108	81	189
2021 Setembro	60	45	105
2021 Agosto	59	62	121
2021 Julho	67	56	123
2021 Junho	58	65	123
2021 Maio	52	90	142
2021 Abril	108	227	335
2021 Mar�o	366	108	474
2021 Fevereiro	388	15	403
2021 Janeiro	393	17	410
2020 Dezembro	394	23	417
2020 Novembro	373	15	388
2020 Outubro	378	19	397
2020 Setembro	391	11	402
2020 Agosto	476	7	483
2020 Julho	212	9	221
2020 Junho	33	13	46
2020 Maio	21	9	30
2020 Abril	0	4	4

Mostrar tudo

Indexada em:

Siga-nos:

Inscreva-se:

Estatísticas

Indexada em:

Siga-nos:

Inscreva-se:

Estatísticas

Receba a nossa Newsletter